

## Author Index

- Abdel-Hay, M.H., see Alkaysi, H.N. (87) 73
- Abu-Bakar, B.B., see Pryce-Jones, R.H. (86) 231
- Acartürk, F., Kışlal, Ö. and Çelebi, N.  
The effect of some natural polymers on the solubility and dissolution characteristics of nifedipine (85) 1
- Acquasaliente, M., see Dal Pozzo, A. (81) 263
- Adjei, A., Rao, S., Garren, J., Menon, G. and Vadnere, M.  
Effect of ion-pairing on 1-octanol-water partitioning of peptide drugs. I: The nonapeptide leuprolide acetate (90) 141
- Aggarwal, N., see Mukherji, G. (86) 153
- Ågren, T., see Tønnesen, H.H. (90) 221
- Aiache, J.-M., see Lootvoet, G. (85) 113
- Akbuğa, J.  
Use of chitosonium malate as a matrix in sustained-release tablets (89) 19
- Albasini, A., see Costantino, L. (86) 17
- Aldén, M., Tegenfeldt, J. and Sjökvist, E.  
Structure of solid dispersions in the system polyethylene glycol-griseofulvin with additions of sodium dodecyl sulphate (83) 47
- Aldén, M., see Sjökvist Saers, E. (90) 105
- Alderborn, G., see Wikberg, M. (84) 191
- Alexander, M., see Ghosh, T.K. (88) 391
- Alkaysi, H.N., Abdel-Hay, M.H., Sheikh Salem, M., Gharraibeh, A.M. and Na'was, T.E.  
Chemical and microbiological investigations of metal ion interaction with norfloxacin (87) 73
- Allémann, E., Gurny, R. and Doelker, E.  
Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size (87) 247
- Alpar, H.O., Bowen, J.C. and Brown, M.R.W.  
Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid (88) 335
- Alsina, M.A., see Colomé, C. (90) 59
- Ambroggi, G., see Leroy, P. (82) 157
- Amidon, G.L., see Oh, D.-M. (85) 181
- Anderson, W., see Pop, E. (84) 39
- Andersson, M., see Stureson, C. (89) 235
- Angberg, M., Nyström, C. and Castensson, S.  
Evaluation of heat-conduction microcalorimetry in pharmaceutical stability studies. V. A new approach for continuous measurements in abundant water vapour (81) 153
- Angberg, M., Nyström, C. and Castensson, S.  
Evaluation of heat-conduction microcalorimetry in pharmaceutical stability studies. VI. Continuous monitoring of the interaction of water vapour with powders and powder mixtures at various relative humidities (83) 11
- Angberg, M., Nyström, C. and Castensson, S.  
Evaluation of heat-conduction microcalorimetry in pharmaceutical stability studies. VII. Oxidation of ascorbic acid in aqueous solution (90) 19
- Aoki, S., Ohwaki, T., Uesugi, K., Tatsuishi, K., Ozawa, H. and Kayano, M.  
Preparation of a novel type of controlled-release carrier and evaluation of drug release from the matrix tablet and its physical properties (85) 29
- Aoki, S., Uesugi, K., Tatsuishi, K., Ozawa, H. and Kayano, M.  
Evaluation of the correlation between in vivo and in vitro release of phenylpropanolamine HCl from controlled-release tablets (85) 65
- Araki, M., Yamashita, S., Nadai, T., Masada, M., Kurosaki, Y., Nakayama, T. and Kimura, T.  
Interaction of percutaneous absorption enhancer with stratum corneum of hamster cheek pouch; an electrophysiological study (81) 39
- Archimbault, P., see Leroy, P. (82) 157
- Arima, H., see Irie, T. (84) 129
- Aritomi, H., see Irie, T. (84) 129
- Armstrong, J.K., see Buckton, G. (83) 115
- Arnaud, P., see Fontan, J.E. (82) 67
- Asano, M., see Imasaka, K. (81) 31
- Ashton, P., Walters, K.A., Brain, K.R. and Hadgraft, J.  
Surfactant effects in percutaneous absorption. I. Effects on the transdermal flux of methyl nicotinate (87) 261
- Ashton, P., Walters, K.A., Brain, K.R. and Hadgraft, J.  
Surfactant effects in percutaneous absorption. II. Effects on protein and lipid structure of the stratum corneum (87) 265
- Asuero, A.G.  
A hyperbolic cosine method for the spectrophotometric evaluation of acidity constants of two-step overlapping equilibria (88) 15
- Asuero, A.G.  
Buffer index in the titration of a monoprotic acid with a strong base (87) 11
- Asuero, A.G.  
Evaluation of acidity constants of dibasic acids and diacid bases from liquid-liquid distribution measurements (89) 103
- Asuero, A.G., see Gonzalez, A.G. (84) R1

- Atanasiu, R. and Radu, A.  
The interaction of cationic nanoparticles with mouse capillary endothelial cells in situ and in vivo (90) 119
- Athanassiou, G.C., Rekkas, D.M. and Choulis, N.H.  
Bioavailability of sulphamethoxazole-trimethoprim spheroidal granules (85) 209
- Athanassiou, G.C., Rekkas, D.M. and Choulis, N.H.  
Correlation of in vitro dissolution data with in vivo plasma concentrations, for three, orally administered, formulations of sulphamethoxazole-trimethoprim, by statistical moments analysis (90) 51
- Attwood, D., Mallon, C. and Taylor, C.J.  
Phase studies on oil-in-water phospholipid microemulsions (84) R5
- Attwood, D., Mallon, C., Ktistis, G. and Taylor, C.J.  
A study on factors influencing the droplet size in nonionic oil-in-water microemulsions (88) 417
- Attwood, D., see Barnwell, S.G. (88) 423
- Attwood, D., see Barnwell, S.G. (89) 245
- Attwood, D., see Cole, S.K. (88) 211
- Augsburger, L.L., see Scott, D.C. (84) 39
- Ausborn, M., see Schreier, H. (87) 183
- Awata, N., see Nakada, Y. (89) 169
- Baert, L., Remon, J.P., Knight, P. and Newton, J.M.  
A comparison between the extrusion forces and sphere quality of a gravity feed extruder and a ram extruder (86) 187
- Baillie, A.J., see Collins, M. (83) 251
- Barber, R.F., see Jurima-Romet, M. (88) 201
- Barnwell, S.G., Laudanski, T., Dwyer, M., Story, M.J., Guard, P., Cole, S. and Attwood, D.  
Reduced bioavailability of atenolol in man: the role of bile acids (89) 245
- Barnwell, S.G., Laudanski, T., Story, M.J., Mallinson, C.B., Harris, R.J., Cole, S.K., Keating, M. and Attwood, D.  
Improved oral bioavailability of propranolol in healthy human volunteers using a liver bypass drug delivery system containing oleic acid (88) 423
- Barnwell, S.G., see Cole, S.K. (88) 211
- Barr, W.H., see Peck, C.C. (82) 9
- Barratt, G., see Yu, W. (89) 139
- Barrow, L., see Watts, P.J. (87) 215
- Barry, B.W., see Williams, A.C. (81) R11
- Barry, B.W., see Williams, A.C. (86) 69
- Basci, N., see Onur, M.A. (88) 313
- Béchar, S.R., Quraishi, O. and Kwong, E.  
Film coating: effect of titanium dioxide concentration and film thickness on the photostability of nifedipine (87) 133
- Bechgaard, E., Gizurarson, S., Jørgensen, L. and Larsen, R.  
The viability of isolated rabbit nasal mucosa in the Ussing chamber, and the permeability of insulin across the membrane (87) 125
- Bechgaard, E., Jørgensen, L., Larsen, R., Gizurarson, S., Carstensen, J. and Hvass, A.  
Insulin and didecanoyl-L- $\alpha$ -phosphatidylcholine: in vitro study of the transport through rabbit nasal mucosal tissue (89) 147
- Beezer, A.E., see Buckton, G. (82) R7
- Beezer, A.E., see Montanari, M.L.C. (85) 199
- Behl, C.R., see Seta, Y. (81) 89
- Behl, C.R., see Shah, V.P. (82) 21
- Beijnen, J.H., see Suenaga, A. (82) 29
- Beijnen, J.H., see Van der Houwen, O.A.G.J. (89) R5
- Bekers, O., see Suenaga, A. (82) 29
- Bekers, O., see Van der Houwen, O.A.G.J. (89) R5
- Beksac, S., see Onur, M.A. (88) 313
- Benamer, H., De Gand, G., Brasseur, R., Van Vooren, J.P. and Legros, F.J.  
Liposome-incorporated dexamethasone palmitate: Chemical and physical properties (89) 157
- Benedetti, L., see Ghezzi, E. (87) 21
- Benet, L.Z., see Peck, C.C. (82) 9
- Benhamou, D., see Bonhomme, L. (84) 33
- Benoit, E., Maincent, P. and Bessière, J.  
Applicability of dielectric measurements to the adsorption of drugs onto nanoparticles (84) 283
- Benoit, J.P., see Mestiri, M. (89) 229
- Benoit, J.P., see Pensé, A.M. (81) 111
- Bergenstrahl, B., see Sjöström, B. (84) 107
- Bergenstrahl, B., see Sjöström, B. (88) 53
- Bernad, M.J., see Veiga, M.D. (89) 119
- Bessière, J., see Benoit, E. (84) 283
- Betageri, G.V. and Parsons, D.L.  
Drug encapsulation and release from multilamellar and unilamellar liposomes (81) 235
- Beten, D.B., Gelbcke, M., Diallo, B. and Moës, A.J.  
Interaction between dipyrindamole and Eudragit S (88) 31
- Beugre, T., see Bonhomme, L. (84) 33
- Beutner, D., see Hadgraft, J. (89) R1
- Beysac, E., see Lootvoet, G. (85) 113
- Bindra, D.S., see Safadi, M. (90) 239
- Bindschaedler, C., see Ibrahim, H. (87) 239
- Biviano, F., see Ghezzi, E. (87) 21
- Blom-Rosemalen, M.C.M., see Noach, A.B.J. (90) 229
- Bloor, J.R., see Wilding, I.R. (83) 155
- Blunk, T., see Müller, R.H. (84) 1
- Bodor, N., see Pop, E. (84) 39
- Bolhuis, G.K., see Riepma, K.A. (85) 121
- Bonhomme, L., Benhamou, D. and Beugre, T.  
Slow-release effect of pH-adjusted bupivacaine: In vitro demonstration (84) 33
- Bonina, F.P. and Montenegro, L.  
Penetration enhancer effects on in vitro percutaneous absorption of heparin sodium salt (82) 171
- Borsadia, S., see Seta, Y. (81) 89
- Botha, S.A. and Flanagan, D.R.  
Characterization of digoxin hydrates using thermal methods (82) 185
- Botha, S.A. and Flanagan, D.R.  
Non-thermal methods in characterization of anhydrous digoxin and two digoxin hydrates (82) 195

- Bouwstra, J.A., Gooris, G.S., Salomons-de Vries, M.A., Van der Spek, J.A. and Bras, W.  
Structure of human stratum corneum as a function of temperature and hydration: A wide-angle X-ray diffraction study (84) 205
- Bouwstra, J.A., see Buckton, G. (83) 115
- Bowen, J.C., see Alpar, H.O. (88) 335
- Brain, K.R., Hadgraft, J., James, V.J., Shah, V.P., Walters, K.A. and Watkinson, A.C.  
In vitro assessment of skin permeation from a transdermal system for the delivery of oestradiol (89) R13
- Brain, K.R., see Ashton, P. (87) 261
- Brain, K.R., see Ashton, P. (87) 265
- Brain, K.R., see Heard, C.M. (90) R5
- Bras, W., see Bouwstra, J.A. (84) 205
- Brasseur, R., see Benameur, H. (89) 157
- Breimer, D.D., see Noach, A.B.J. (90) 229
- Brewster, M.E., see Pop, E. (84) 39
- Brown, M.R.W., see Alpar, H.O. (88) 335
- Bruner, M.W., see Burke, C.J. (86) 89
- Brunet, C., see Faouzi, M.A. (89) 125
- Buchmann, M., see Ruelle, P. (87) 47
- Buckton, G. and Beezer, A.E.  
The relationship between particle size and solubility (82) R7
- Buckton, G., Chowdhry, B.Z., Armstrong, J.K., Leharne, S.A., Bouwstra, J.A. and Hofland, H.E.J.  
The use of high-sensitivity differential scanning calorimetry to characterise dilute aqueous dispersions of surfactants (83) 115
- Buckton, G., see Parsons, G.E. (82) 145
- Buckton, G., see Parsons, G.E. (83) 163
- Buckton, G., see Pinto, J.F. (83) 187
- Buitendijk, H.H., see Van der Veen, J. (87) 161
- Bult, A., see Van der Houwen, O.A.G.J. (89) R5
- Bundgaard, H. and Friis, G.J.  
Prodrugs of peptides. 16. Isocyclosporin A as a potential prodrug of cyclosporin A (82) 85
- Bundgaard, H., see Friis, G.J. (82) 79
- Bundgaard, H., see Hansen, J. (81) 253
- Bundgaard, H., see Hansen, L.B. (84) 253
- Bundgaard, H., see Hansen, L.B. (88) 221
- Bundgaard, H., see Hansen, L.B. (88) 229
- Bundgaard, H., see Hansen, L.B. (88) 237
- Bundgaard, H., see Hansen, L.B. (88) 243
- Bundgaard, H., see Kurono, Y. (81) 179
- Bundgaard, H., see Møss, J. (82) 91
- Bunge, A.L., see Watkinson, A.C. (83) 171
- Bunge, A.L., see Watkinson, A.C. (87) 175
- Buri, P., see Ibrahim, H. (87) 239
- Burke, C.J., Steadman, B.L., Volkin, D.B., Tsai, P.-K., Bruner, M.W. and Middaugh, C.R.  
The adsorption of proteins to pharmaceutical container surfaces (86) 89
- Busquets, M.A., see Colomé, C. (90) 59
- Cadórniga, R., see Torrado, S. (86) 147
- Čajkovac, M., see Škalko, N. (85) 97
- Callegaro, L., see Ghezzi, E. (87) 21
- Camber, O., see Prisell, P.T. (85) 51
- Caputo, O., see Cavalli, R. (89) R9
- Caraballo, I., Rabasco, A.M. and Fernández-Arévalo, M.  
Study of thimerosal degradation mechanism (89) 213
- Carelli, V., Di Colo, G., Nannipieri, E. and Serafini, M.F.  
Bile acids as enhancers of steroid penetration through excised hairless mouse skin (89) 81
- Carelli, V., Di Colo, G., Nannipieri, E. and Serafini, M.F.  
Enhancement effects in the permeation of Alprazolam through hairless mouse skin (88) 89
- Carlfors, J., see Stuesson, C. (89) 235
- Carpenter, B.G., see Mortazavi, S.A. (83) 221
- Carstensen, J., see Bechgaard, E. (89) 147
- Carstensen, J.T. and Li Wan Po, A.  
The state of water in drug decomposition in the moist solid state: Description and modelling (83) 87
- Carter, K.C., see Collins, M. (83) 251
- Castelli, F., Puglisi, G., Giammona, G. and Ventura, C.A.  
Effect of the complexation of some nonsteroidal anti-inflammatory drugs with  $\beta$ -cyclodextrin on the interaction with phosphatidylcholine liposomes (88) 1
- Castensson, S., see Angberg, M. (81) 153
- Castensson, S., see Angberg, M. (83) 11
- Castensson, S., see Angberg, M. (90) 19
- Catellani, P.L., Santi, P., Gasperini, E., Ciceri, S., Dondi, G. and Colombo, P.  
Centrifugal die filling system in a new rotary tablet machine (88) 285
- Catellani, P.L., see Colombo, P. (88) 99
- Cavallaro, G., Giammona, G., La Manna, G., Palazzo, S., Pitarresi, G. and Turco Liveri, V.  
Viscosimetric investigation of the interaction between sodium dodecylsulfate micelles and a polymer drug carrier (90) 195
- Cavalli, R., Caputo, O. and Gasco, M.R.  
Solid lipospheres of doxorubicin and idarubicin (89) R9
- Cazin, J.C., see Faouzi, M.A. (89) 125
- Cazin, M., see Faouzi, M.A. (89) 125
- Çelebi, N., see Acartürk, F. (85) 1
- Cerezo, A., see Fernández, M. (84) 197
- Cerezo, A., see Margarit, M.V. (81) 67
- Chafetz, L., see Neau, S.H. (82) 151
- Chaing, C.H., see Law, S.L. (84) 161
- Chan, S.Y. and Li Wan Po, A.  
Quantitative assessment of non-steroidal anti-inflammatory topical products in nicotine-induced erythema using tristimulus colour analysis (83) 73
- Chantres, J.R., see Sainz, M.C. (89) 183
- Charman, W.N., McCrossin, L.E., Pochopin, N.L. and Munro, S.L.A.  
Study of the relative lactonization rates of pilocarpic acid and isopilocarpic acid in acidic media (88) 397

- Chatham, S.M., see Parsons, G.E. (82) 145
- Chatham, S.M., see Parsons, G.E. (83) 163
- Chaumeil, J.C., see Fontan, J.E. (82) 67
- Chawla, A., see Taylor, K.M.G. (85) 203
- Chen, C.-F., see Tsai, T.-H. (84) 279
- Chen, C.-Y., see Ho, H.-O. (90) 95
- Chen, D., see Ohta, N. (85) 39
- Chen, J.R., see Shah, J.C. (84) 223
- Chen, W.-G. and Hwang, G.C.-C.  
Adhesive and in vitro release characteristics of propranolol bioadhesive disc system (82) 61
- Chiao, C.S., see Ghosh, T.K. (82) 39
- Chien, Y.W., see Nair, M. (89) 41
- Chien, Y.W., see Shah, H.S. (86) 167
- Childs, K., see Ghosh, T.K. (88) 391
- Chou, H.-L., see Sheu, M.-T. (85) 57
- Choudhari, K.B. and Sanghavi, N.M.  
Dissolution behaviour and characterization of diazepam-Pullulan coground mixtures (89) 207
- Choudhury, S. and Nelson, K.F.  
Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl- $\beta$ -cyclodextrin (85) 175
- Choulis, N.H., see Athanassiou, G.C. (85) 209
- Choulis, N.H., see Athanassiou, G.C. (90) 51
- Choulis, N.H., see Papadimitriou, E. (86) 131
- Choulis, N.H., see Vlachou, M.D. (82) 47
- Chow, D., see Shah, J.C. (84) 223
- Chow, M.Y., see Neau, S.H. (82) 151
- Chowdhry, B.Z., see Buckton, G. (83) 115
- Christrup, L.L., see Hansen, L.B. (84) 253
- Christrup, L.L., see Hansen, L.B. (88) 221
- Christrup, L.L., see Hansen, L.B. (88) 229
- Christrup, L.L., see Hansen, L.B. (88) 237
- Christrup, L.L., see Hansen, L.B. (88) 243
- Ciceri, S., see Catellani, P.L. (88) 285
- Cini, M., see Saettone, M.F. (86) 159
- Cole, S., see Barnwell, S.G. (89) 245
- Cole, S.K., Story, M.J., Attwood, D., Laudanski, T., Robertson, J. and Barnwell, S.G.  
Studies using a non-ionic surfactant-containing drug delivery system designed for hard gelatin capsule compatibility (88) 211
- Cole, S.K., see Barnwell, S.G. (88) 423
- Collins, J., see Peck, C.C. (82) 9
- Collins, M., Baillie, A.J. and Carter, K.C.  
Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection: II. Changes in tissue drug distribution (83) 251
- Colombo, P., Catellani, P.L., Peppas, N.A., Maggi, L. and Conte, U.  
Swelling characteristics of hydrophilic matrices for controlled release. New dimensionless number to describe the swelling and release behavior (88) 99
- Colombo, P., see Catellani, P.L. (88) 285
- Colomé, C., Alsina, M.A., Busquets, M.A., Haro, I. and Reig, F.  
Interaction of aminoglycosides and colistin with model membranes: Liposomes and monolayers (90) 59
- Conte, U., see Colombo, P. (88) 99
- Conte, U., see Giunchedi, P. (85) 141
- Conti, B., see Pavanetto, F. (84) 151
- Cook, C.E., see Shah, V.P. (82) 1
- Cornett, C., see Jensen, J. (88) 177
- Cornwell, P.A., see Williams, A.C. (86) 69
- Corrigan, O.I., see Healy, A.M. (84) 167
- Corrigan, O.I., see McGloughlin, R.M.R. (82) 135
- Coskun, T., see Onur, M.A. (88) 313
- Costantino, L., Rastelli, G. and Albasini, A.  
Inhibitory activity of flavonols towards the xanthine oxidase enzyme (86) 17
- Couarraze, G., see Husson, I. (86) 113
- Coutel-Egros, A., Maitani, Y., Veillard, M., Machida, Y. and Nagai, T.  
Combined effects of pH, cosolvent and penetration enhancers on the in vitro buccal absorption of propranolol through excised hamster cheek pouch (84) 117
- Couvreur, P., see Lherm, C. (84) 13
- Couvreur, P., see Müller, R.H. (84) 1
- Craig, D.Q.M., see Sjökvist Saers, E. (83) 211
- Dallas, P.P., see Vlachou, M.D. (82) 47
- Dal Pozzo, A. and Acquasaliente, M.  
New highly water-soluble phenytoin prodrugs (81) 263
- Davies, M.C., see Porter, C.J.H. (83) 273
- Davies, M.C., see Watts, P.J. (87) 215
- Davies, N.M., see Durrani, A.M. (88) 409
- Davis, S.S., Illum, L., Washington, C. and Harper, G.  
Studies on the interaction of charge-reversed emulsions with the reticuloendothelial system (82) 99
- Davis, S.S., see Porter, C.J.H. (83) 273
- Davis, S.S., see Wilding, I.R. (83) 155
- Davis, S.S., see Wilding, I.R. (84) 59
- Deasy, P.B., Finan, M.P., Klatt, P.R. and Hornykiewytch, T.  
Design and evaluation of a biodegradable implant for improved delivery of oestradiol-17 $\beta$  to steers (89) 251
- Deasy, P.B., see Hilton, A.K. (86) 79
- De Boer, A.G., see Noach, A.B.J. (90) 229
- De Boer, A.H., see Riepma, K.A. (85) 121
- De Gand, G., see Benameur, H. (89) 157
- Deguchi, Y., see Terasaki, T. (81) 143
- Dekker, B.G., see Riepma, K.A. (87) 149
- Dekker, B.G., see Riepma, K.A. (90) R1
- Delgado, A., see Munguia, O. (86) 107
- Del Olmo, E., Toth, I., Fonteh, A.N. and Gibbons, W.A.  
Lipid methyl transferase inhibitory activity of novel  $\alpha$ -amino alkylic acid derivatives (81) 267
- Del Olmo Fernandez, E., see Tóth, I. (83) 131
- De Muynck, C. and Remon, J.P.  
Influence of fat composition on the melting behaviour and on the in vitro release of indomethacin suppositories (85) 103
- Derendorf, H., see Schreier, H. (87) 183
- De Ronde, H.A.G., see Van Amerongen, I.A. (86) 9

- Desjardins, R.E., see Peck, C.C. (82) 9
- De Villiers, M.M., Van der Watt, J.G. and Lötter, A.P.  
Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide (88) 275
- Devissaguet, J.P., see Yu, W. (89) 139
- De Zeeuw, R.A., see Swart, P.J. (87) 67
- De Zeeuw, R.A., see Swart, P.J. (88) 165
- Diallo, B., see Beten, D.B. (88) 31
- Di Colo, G., see Carelli, V. (88) 89
- Di Colo, G., see Carelli, V. (89) 81
- Dighe, S., see Shah, V.P. (82) 1
- Di Giulio, A., Saletti, M.A., Impagnatiello, A., Lucarelli, M., Strom, R. and Oratore, A.  
Encapsulation and efflux of lactone and hydroxy acid forms of simvastatin in reverse-phase evaporation vesicles (89) 133
- Dine, T., see Faouzi, M.A. (89) 125
- Dittgen, M., see Lukowski, G. (84) 23
- Djordjevic, N.M., Rohr, G., Hinterleitner, M. and Schreiber, B.  
Adsorption of water on cyclosporin A, from zero to finite surface coverage (81) 21
- Doelker, E., see Allémann, E. (87) 247
- Doelker, E., see Ibrahim, H. (87) 239
- Dominguez-Gil, A., see Lanao, J.M. (86) 123
- Donaldson, J.D., Roberts, M.S. and Polack, A.E.  
Uptake of solutes by plastic infusion tubing Mathematical solutions (88) 351
- Dondi, G., see Catellani, P.L. (88) 285
- Dowty, M.E., Knuth, K.E. and Robinson, J.R.  
Enzyme characterization studies on the rate-limiting barrier in rabbit buccal mucosa (88) 293
- Duchêne, D., see Irache, J.M. (90) R9
- Durrani, A.M., Davies, N.M., Thomas, M. and Kellaway, I.W.  
Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system (88) 409
- Durrer, C., see Irache, J.M. (90) R9
- Dwivedi, S.K., Sattari, S., Jamali, F. and Mitchell, A.G.  
Ibuprofen racemate and enantiomers: Phase diagram, solubility and thermodynamic studies (87) 95
- Dwyer, M., see Barnwell, S.G. (89) 245
- Eccleston, G.M., see Pryce-Jones, R.H. (86) 231
- Edelsten, M., see Pedersen, M. (90) 247
- Edman, P., see Rydén, L. (83) 1
- Edsman, K., see Stureson, C. (89) 235
- Edwards, H.G.M., see Williams, A.C. (81) R11
- Efentakis, M.  
Release kinetics of flurbiprofen from hydrophobic heterogeneous matrices containing surfactants (85) R1
- Efentakis, M., see Papadimitriou, E. (86) 131
- El-Khordagui, L.K.  
Effect of sodium salicylate on the solution properties of sodium dodecyl sulphate (83) 53
- Elberse, P.A., see Riepma, K.A. (90) R1
- Elkinton, S.K., see Ross, D.L. (88) 379
- Elorza, B., see Sainz, M.C. (89) 183
- Elorza, M.A., see Sainz, M.C. (89) 183
- Elsabee, M. and Prankerd, R.J.  
Solid-state properties of drugs. II. Peak shape analysis and deconvolution of overlapping endotherms in differential scanning calorimetry of chiral mixtures (86) 211
- Elsabee, M. and Prankerd, R.J.  
Solid-state properties of drugs. III. Differential scanning calorimetry of chiral drug mixtures existing as racemic solid solutions, racemic mixtures or racemic compounds (86) 221
- Endo, H., see Kohri, N. (81) 49
- Enever, R.P., see Shahjahan, M. (82) 215
- Enever, R.P., see Shahjahan, M. (82) 223
- Enever, R.P., see Shahjahan, M. (82) 229
- Engblom, J., see Engström, S. (86) 137
- Engström, S., Lindahl, L., Wallin, R. and Engblom, J.  
A study of polar lipid drug carrier systems undergoing a thermoreversible lamellar-to-cubic phase transition (86) 137
- Enthoven, R., see Zanen, P. (81) 199
- Escobar, C., see Veiga, M.D. (89) 119
- Esposito, E., see Nastruzzi, C. (90) 43
- Etman, M.A., Ismail, F.A. and Nada, A.H.  
Effect of metoclopramide on ketoprofen pharmacokinetics in man (88) 433
- Evora, C., see Munguia, O. (86) 107
- Evora, C.M., see Sánchez, E. (83) 59
- Faouzi, M.A., Dine, T., Luyckx, M., Goudaliez, F., Mallevais, M.L., Brunet, C., Cazin, M., Gressier, B. and Cazin, J.C.  
Stability and compatibility studies of pefloxacin, ofloxacin and ciprofloxacin with PVC infusion bags (89) 125
- Fariña, J., see Munguia, O. (86) 107
- Farraj, N.F., see Richardson, J.L. (88) 319
- Fernández-Arévalo, M., see Caraballo, I. (89) 213
- Fernández, M., Rodríguez, I.C., Margarit, M.V. and Cerezo, A.  
Characterization of solid dispersions of piroxicam/polyethylene glycol 4000 (84) 197
- Fessi, H., see Yu, W. (89) 139
- Fielden, K.E., Newton, J.M. and Rowe, R.C.  
A comparison of the extrusion and spheronization behaviour of wet powder masses processed by a ram extruder and a cylinder extruder (81) 225
- Fielden, K.E., Newton, J.M. and Rowe, R.C.  
The influence of lactose particle size on spheronization of extrudate processed by a ram extruder (81) 205
- Finan, M.P., see Deasy, P.B. (89) 251
- Finne, U. and Urtti, A.  
Pharmacokinetic simulation reveals in vivo deviations from in vitro release of timolol from polymer matrices (84) 217
- Fitzgerald, P., Wilson, C.G., Greaves, J.L., Frier, M., Hollingsbee, D., Gilbert, D. and Richardson, M.  
Scintigraphic assessment of the precorneal residence of a new ophthalmic delivery system (NODS) in man (83) 177
- Flanagan, D.R., see Botha, S.A. (82) 185
- Flanagan, D.R., see Botha, S.A. (82) 195

- Florence, A.T., see Jani, P.U. (84) 245  
 Florence, A.T., see Jani, P.U. (86) 239  
 Flynn, G.L., see Shah, V.P. (82) 21  
 Fontan, J.E., Arnaud, P. and Chaumeil, J.C.  
 Effects of polysorbate 80 on the pharmacokinetics of a carbamazepine suppository in the rabbit (82) 67  
 Fonteh, A.N., see Del Olmo, E. (81) 267  
 Fowler, S. and Jones, D.S.  
 Modified adherence of *Candida albicans* to human buccal epithelial cells in vitro following treatment with cationic, non-antibiotic antimicrobial agents (84) 77  
 Fowler, S. and Jones, D.S.  
 Modified adherence of *Candida albicans* to human buccal epithelial cells in vitro following treatment with cationic, non-antibiotic antimicrobial agents (86) 193  
 Frier, M., see Fitzgerald, P. (83) 177  
 Friis, G.J. and Bundgaard, H.  
 Kinetics of degradation of cyclosporin A in acidic aqueous solution and its implication in its oral absorption (82) 79  
 Friis, G.J., see Bundgaard, H. (82) 85  
 Fujita, T., see Nishikawa, M. (85) 75  
 Fukuzaki, H., see Imasaka, K. (81) 31  
 Fullerton, A., see Hansen, L.B. (84) 253  
 Furst, D.E., see Peck, C.C. (82) 9
- Gabr, K.E., see Meshali, M.M. (89) 177  
 Gambari, R., see Nastruzzi, C. (90) 43  
 Gandhi, R. and Robinson, J.  
 Mechanisms of penetration enhancement for transbuccal delivery of salicylic acid (85) 129  
 Garr, J.S.M. and Rubinstein, M.H.  
 Consolidation and compaction characteristics of a three-component particulate system (82) 71  
 Garr, J.S.M. and Rubinstein, M.H.  
 The influence of moisture content on the consolidation and compaction properties of paracetamol (81) 187  
 Garren, J., see Adjei, A. (90) 141  
 Gasco, M.R., see Cavalli, R. (89) R9  
 Gasperini, E., see Catellani, P.L. (88) 285  
 Gavriloff, C., see Leroy, P. (82) 157  
 Gelbcke, M., see Beten, D.B. (88) 31  
 Genta, I., see Pavanetto, F. (84) 151  
 Ghanem, A.H., see Seta, Y. (81) 89  
 Gharaibeh, A.M., see Alkaysi, H.N. (87) 73  
 Ghebre-Sellassie, I., see Yang, S.T. (86) 247  
 Ghezzi, E., Benedetti, L., Rochira, M., Biviano, F. and Callegaro, L.  
 Hyaluronane derivative microspheres as NGF delivery devices: Preparation methods and in vitro release characterization (87) 21  
 Ghosh, T.K., Chiao, C.S. and Gokhale, R.D.  
 In vitro release and permeation of levobunolol from various transdermal formulations (82) 39  
 Ghosh, T.K., Habib, M.J., Childs, K. and Alexander, M.  
 Transdermal delivery of metoprolol I: Comparison between hairless mouse and human cadaver skin and effect of *n*-decylmethyl sulfoxide (88) 391
- Giammona, G., see Castelli, F. (88) 1  
 Giammona, G., see Cavallaro, G. (90) 195  
 Giannaccini, B., see Saettone, M.F. (86) 159  
 Gibbons, W.A., see Del Olmo, E. (81) 267  
 Gibbons, W.A., see Tóth, I. (83) 131  
 Gibbons, W.A., see Valkó, K. (83) 123  
 Gibbons, W.A., see Wood, I.P. (87) 141  
 Gilbert, D., see Fitzgerald, P. (83) 177  
 Gilligan, C.A., see Wong, L.P. (83) 95  
 Giunchedi, P., Conte, U., Maggi, L. and La Manna, A.  
 Hydrophilic matrices for the extended release of a model drug exhibiting pH-dependent solubility (85) 141  
 Giunchedi, P., see Pavanetto, F. (84) 151  
 Gizurarson, S., see Bechgaard, E. (87) 125  
 Gizurarson, S., see Bechgaard, E. (89) 147  
 Gokhale, R.D., see Ghosh, T.K. (82) 39  
 Gomišček, S., see Sher, A. (90) 181  
 Gonzalez, A.G., Herrador, M.A. and Asuero, A.G.  
 Evaluation of ionization constants of drugs in aqueous organic mixtures from reversed phase high-performance liquid chromatography (84) R1  
 Gonzalez-Rothi, R.J., see Schreier, H. (87) 183  
 Gooris, G.S., see Bouwstra, J.A. (84) 205  
 Gorman, S.P., see Woolfson, A.D. (84) 69  
 Gouda, M.W.  
 Effect of an antidiarrhoeal mixture on the bioavailability of tetracycline (89) 75  
 Goudaliez, F., see Faouzi, M.A. (89) 125  
 Graffner, C., see Waaler, P.J. (87) 229  
 Graham, E.T., see Kontny, M.J. (84) 261  
 Grant, D.J.W., see Khankari, R.K. (82) 117  
 Greaves, J.L., see Fitzgerald, P. (83) 177  
 Greenhill, J.V., see Hjorth Tønnesen, H. (87) 79  
 Gressier, B., see Faouzi, M.A. (89) 125  
 Griffin, R.J., see Naik, A. (89) 51  
 Griffin, R.J., see Naik, A. (89) 65  
 Griffin, R.J., see Naik, A. (90) 129  
 Gröning, R.  
 Computer-controlled release of metoprolol from capsules (87) 89  
 Grove, J., see Thermes, F. (81) 59  
 Guard, P., see Barnwell, S.G. (89) 245  
 Guillory, J.K., see Hartauer, K.J. (85) 163  
 Gurny, R., see Allémann, E. (87) 247  
 Gurny, R., see Ibrahim, H. (87) 239  
 Guy, R.H. and Hadgraft, J.  
 Rate control in transdermal drug delivery? (82) R1
- Habib, M.J., see Ghosh, T.K. (88) 391  
 Hadgraft, J., Beutner, D. and Wolff, H.M.  
 In vivo-in vitro comparisons in the transdermal delivery of nitroglycerin (89) R1  
 Hadgraft, J., see Ashton, P. (87) 261  
 Hadgraft, J., see Ashton, P. (87) 265  
 Hadgraft, J., see Brain, K.R. (89) R13  
 Hadgraft, J., see Guy, R.H. (82) R1  
 Hadgraft, J., see Heard, C.M. (90) R5

- Hadgraft, J., see Watkinson, A.C. (83) 171
- Hadgraft, J., see Watkinson, A.C. (87) 175
- Hafeez, R.A., see Tóth, I. (83) 131
- Hammouda, Y.E., Kasim, N.A. and Nada, A.H.  
Formulation and in vitro evaluation of verapamil HCl suppositories (89) 111
- Han, K.S., see Lee, S.H. (90) 81
- Hancock, B.C., York, P. and Rowe, R.C.  
Characterization of wet masses using a mixer torque rheometer: 2. Mixing kinetics (83) 147
- Hansen, J., Mørk, N. and Bundgaard, H.  
Phenyl carbamates of amino acids as prodrug forms for protecting phenols against first-pass metabolism (81) 253
- Hansen, L.B., Christrup, L.L. and Bundgaard, H.  
Enhanced delivery of ketobemidone through porcine buccal mucosa in vitro via more lipophilic ester prodrugs (88) 237
- Hansen, L.B., Christrup, L.L. and Bundgaard, H.  
Ketobemidone prodrugs for buccal delivery: Prediction of the extent of saliva-catalyzed hydrolysis of various ester prodrugs under simulated in vivo conditions (88) 229
- Hansen, L.B., Christrup, L.L. and Bundgaard, H.  
Saliva-catalyzed hydrolysis of a ketobemidone ester prodrug: Factors influencing human salivary esterase activity (88) 221
- Hansen, L.B., Fullerton, A., Christrup, L.L. and Bundgaard, H.  
Enhanced transdermal delivery of ketobemidone with prodrugs (84) 253
- Hansen, L.B., Jørgensen, A., Rasmussen, S.N., Christrup, L.L. and Bundgaard, H.  
Buccal absorption of ketobemidone and various ester prodrugs in the rat (88) 243
- Hansen, S.H., see Jensen, J. (88) 177
- Haro, I., see Colomé, C. (90) 59
- Harper, G., see Davis, S.S. (82) 99
- Harris, R.J., see Barnwell, S.G. (88) 423
- Hartauer, K.J., Miller, E.S. and Guillory, J.K.  
Diffuse reflectance infrared Fourier transform spectroscopy for the quantitative analysis of mixtures of polymorphs (85) 163
- Harter, J.G., see Peck, C.C. (82) 9
- Hashida, M., see Nishikawa, M. (85) 75
- Hashida, M., see Yamashita, F. (89) 199
- Hassan, I., see Nicklin, P. (83) 197
- Hatano, K., see Kurono, Y. (81) 179
- Hayashibara, M., see Nagasako, S. (81) 127
- Hayes, G., see Wilding, I.R. (83) 155
- Healy, A.M. and Corrigan, O.I.  
Predicting the dissolution rate of ibuprofen-acidic excipient compressed mixtures in reactive media (84) 167
- Heard, C.M., Watkinson, A.C., Brain, K.R. and Hadgraft, J.  
In vitro skin penetration of propranolol enantiomers (90) R5
- Heng, P.W.S., see Wan, L.S.C. (88) 159
- Herbort, J., see Müller, R.H. (84) 1
- Herrador, M.A., see Gonzalez, A.G. (84) R1
- Higuchi, W.I., see Seta, Y. (81) 89
- Higuchi, W.I., see Shah, V.P. (82) 21
- Hilton, A.K. and Deasy, P.B.  
In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxicillin trihydrate (86) 79
- Hino, T., see Kawashima, Y. (89) 9
- Hino, T., see Ohwaki, T. (85) 19
- Hino, T., see Takeuchi, H. (86) 25
- Hinterleitner, M., see Djordjevic, N.M. (81) 21
- Hirota, S., see Yamauchi, H. (90) 73
- Hiselius, J., see Prisell, P.T. (85) 51
- Hjorth Tønnesen, H. and Greenhill, J.V.  
Studies on curcumin and curcuminoids. XXII: Curcumin as a reducing agent and as a radical scavenger (87) 79
- Ho, H.-O. and Chen, C.-Y.  
Diffusion characteristics of fibrin films (90) 95
- Hofland, H.E.J., see Buckton, G. (83) 115
- Holborow, D., see Medicott, N.J. (84) 85
- Holinej, J., see Johnson, J.L. (90) 151
- Holley, J.L., see Tóth, I. (83) 131
- Holley, J.L., see Wood, I.P. (87) 141
- Hollingsbee, D., see Fitzgerald, P. (83) 177
- Holman, L.E.  
The normalization of the solid fraction of particulate compacts (89) R17
- Hornykiewytsch, T., see Deasy, P.B. (89) 251
- Horton, R.J., see Wilding, I.R. (84) 59
- Husson, I., Leclerc, B., Spenlehauer, G., Veillard, M., Puisieux, F. and Couarraze, G.  
Influence of size polydispersity on drug release from coated pellets (86) 113
- Hvass, A., see Bechgaard, E. (89) 147
- Hwang, G.C.-C., see Chen, W.-G. (82) 61
- Hwang, S.-J., see Kim, C.-K. (89) 91
- Ibrahim, H., Bindschaedler, C., Doelker, E., Buri, P. and Gurny, R.  
Aqueous nanodispersions prepared by a salting-out process (87) 239
- Ikeda, K., see Kurono, Y. (81) 179
- Ikeda, K., see Ohta, N. (85) 39
- Illum, L., see Davis, S.S. (82) 99
- Illum, L., see Porter, C.J.H. (83) 273
- Illum, L., see Richardson, J.L. (88) 319
- Imasaka, K., Yoshida, M., Fukuzaki, H., Asano, M., Kumakura, M., Mashimo, T., Yamanaka, H. and Nagai, T.  
New biodegradable polymers of L-lactic acid and aromatic hydroxy acids and their applications in drug delivery systems (81) 31
- Impagnatiello, A., see Di Giulio, A. (89) 133
- Iqbal, M., see Irwin, W.J. (83) 241
- Irache, J.M., Durrer, C., Ponchel, G. and Duchêne, D.  
Determination of particle concentration in latexes by turbidimetry (90) R9
- Irie, T., Wakamatsu, K., Arima, H., Aritomi, H. and Uekama, K.

- Enhancing effects of cyclodextrins on nasal absorption of insulin in rats (84) 129
- Irwin, B., see Nicklin, P. (83) 197
- Irwin, W.J. and Iqbal, M.  
Bropirimine formulation: The dynamic testing of injections (83) 241
- Irwin, W.J., see Naik, A. (89) 51
- Irwin, W.J., see Naik, A. (89) 65
- Irwin, W.J., see Naik, A. (90) 129
- Iseki, K., see Kohri, N. (81) 49
- Isimer, A., see Onur, M.A. (88) 313
- Ismail, F.A., see Etman, M.A. (88) 433
- Ito, S., see Ohta, N. (85) 39
- Iwakawa, S., see Okumura, K. (88) 63
- Iwakura, Y., see Morimoto, K. (81) 119
- Iwamoto, K., see Nagasako, S. (81) 127
- Iwamoto, T., see Kawashima, Y. (89) 9
- Izutsu, K.-i., Yoshioka, S. and Terao, T.  
Stabilization of  $\beta$ -galactosidase by amphiphilic additives during freeze-drying (90) 187
- Jacobsen, L., see Jørgensen, K. (88) 23
- Jager, R.S., see Riepma, K.A. (90) R1
- Jalšenjak, I., see Škalko, N. (85) 97
- Jamali, F., see Dwivedi, S.K. (87) 95
- James, V.J., see Brain, K.R. (89) R13
- Jang, S.H., Lee, S.H., Ryoo, S.H., Kim, S.H. and Lee, M.G.  
Dose-independent pharmacokinetics of recombinant human interferon- $\alpha$  in rabbits (84) 273
- Jang, S.H., see Lee, S.H. (90) 81
- Jani, P.U., Florence, A.T. and McCarthy, D.E.  
Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat (84) 245
- Jani, P.U., McCarthy, D.E. and Florence, A.T.  
Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose (86) 239
- Jensen, J., Cornett, C., Olsen, C.E., Tjørnelund, J. and Hansen, S.H.  
Identification of major degradation products of 5-aminosalicylic acid formed in aqueous solutions and in pharmaceuticals (88) 177
- Jeong, K.-H., see Lee, S.H. (90) 81
- Jian, L. and Po, A.L.W.  
Effect of xylometazoline and antazoline on ciliary beat frequency (86) 59
- Jiménez-Castellanos, M.R., Zia, H. and Rhodes, C.T.  
Assessment of an in vitro method for measuring the bioadhesiveness of tablets (89) 223
- Johnson, J.L., Holinej, J. and Williams, M.D.  
Influence of ionic strength on matrix integrity and drug release from hydroxypropyl cellulose compacts (90) 151
- Jones, B.E., see Thomas, M. (83) 139
- Jones, D.S., see Fowler, S. (84) 77
- Jones, D.S., see Fowler, S. (86) 193
- Jones, D.S., see Medicott, N.J. (84) 85
- Jordan, C.G.M., Quigley, J.M. and Timoney, R.F.  
Synthesis, hydrolysis kinetics and lipophilicity of *O*-acyl esters of oxprenolol (84) 175
- Jørgensen, A., see Hansen, L.B. (88) 243
- Jørgensen, K. and Jacobsen, L.  
Factorial design used for ruggedness testing of flow through cell dissolution method by means of Weibull transformed drug release profiles (88) 23
- Jørgensen, L., see Bechgaard, E. (87) 125
- Jørgensen, L., see Bechgaard, E. (89) 147
- Jung, B.-H., see Shim, C.-K. (82) 233
- Jung, B.-H., see Shim, C.-K. (83) 257
- Juppo, A.M., Yliuusi, J., Kervinen, L. and Ström, P.  
Determination of size distribution of lactose, glucose and mannitol granules by sieve analysis and laser diffractometry (88) 141
- Jurima-Romet, M., Barber, R.F. and Shek, P.N.  
Liposomes and bronchoalveolar lavage fluid: Release of vesicle-entrapped glutathione (88) 201
- Kadir, F., Seijsener, C.B.J. and Zuidema, J.  
Influence of the injection volume on the release pattern of intramuscularly administered propranolol to rats (81) 193
- Kanfer, I., see Skinner, M. (88) 151
- Kao, C.-C., see Sheu, M.-T. (85) 57
- Karlsen, J., see Tønnesen, H.H. (90) 221
- Karnik, N.A., see Moelands, D. (86) 263
- Kasama, Y., see Terasaki, T. (81) 143
- Kasim, N.A., see Hammouda, Y.E. (89) 111
- Katagiri, Y., see Nagasako, S. (81) 127
- Kato, S., see Kurono, Y. (81) 179
- Kaul, D., Nguyen, N.T. and Venkataram, S.  
Crystal habit modifications and altered tableting characteristics (88) 345
- Kawashima, Y., Iwamoto, T., Niwa, T., Takeuchi, H. and Hino, T.  
Uniform and improved bioavailability of newly developed rapid and sustained release suspensions of ibuprofen microspheres (89) 9
- Kawashima, Y., see Ohwaki, T. (85) 19
- Kawashima, Y., see Takeuchi, H. (86) 25
- Kayano, M., see Aoki, S. (85) 29
- Kayano, M., see Aoki, S. (85) 65
- Keating, M., see Barnwell, S.G. (88) 423
- Kellaway, I.W., see Durrani, A.M. (88) 409
- Kellaway, I.W., see Thomas, M. (83) 139
- Kerč, J., Srčič, S., Kofler, B. and Šmid-Korbar, J.  
Molar solubility of felodipine in different aqueous systems (81) R1
- Kerč, J., see Srčič, S. (87) 1
- Kervinen, L., see Juppo, A.M. (88) 141
- Kesselring, U.W., see Ruelle, P. (87) 47
- Khan, M.Z.I., Tucker, I.G. and Opdebeeck, J.P.  
Evaluation of cholesterol-lecithin implants for sustained delivery of antigen: release in vivo and single-step immunisation of mice (90) 255



- Khankari, R.K., Law, D. and Grant, D.J.W.  
Determination of water content in pharmaceutical hydrates by differential scanning calorimetry (82) 117
- Kido, M., see Nakamura, J. (87) 59
- Kikuchi, H., see Yamauchi, H. (90) 73
- Kim, C.-K., Hwang, S.-J. and Lee, M.G.  
The organ targetability of small and large albumin microspheres containing free and HSA conjugated methotrexate (89) 91
- Kim, I.S., see Lee, S.H. (90) 81
- Kim, S.H., see Jang, S.H. (84) 273
- Kimura, T., see Araki, M. (81) 39
- Kimura, T., see Kurosaki, Y. (82) 165
- Kinget, R., see Van den Mooter, G. (87) 37
- Kirby, C.J., see Onur, M.A. (88) 313
- Kiryama, A., see Ushirogawa, Y. (81) 133
- Kışlal, Ö., see Acartürk, F. (85) 1
- Klatt, P.R., see Deasy, P.B. (89) 251
- Klooster, N.T.M., see Van Amerongen, I.A. (86) 9
- Knapczyk, J.  
Antimycotic buccal and vaginal tablets with chitosan (88) 9
- Knapczyk, J.  
Excipient ability of chitosan for direct tableting (89) 1
- Knight, P., see Baert, L. (86) 187
- Knuth, K.E., see Dowty, M.E. (88) 293
- Kofler, B., see Kerč, J. (81) R1
- Kofler, B., see Srčić, S. (87) 1
- Kohri, N., Miyata, N., Takahashi, M., Endo, H., Iseki, K., Miyazaki, K., Takechi, S. and Nomura, A.  
Evaluation of pH-independent sustained-release granules of dipyrindamole by using gastric-acidity-controlled rabbits and human subjects (81) 49
- Koizumi, K., see Suenaga, A. (82) 29
- Kok, W.J.J. and Vrijhof, W.P.  
Impairment of carbamazepine tablet disintegration in patients (86) 259
- Kolli, M., Montheard, J.P. and Vergnaud, J.M.  
Release of benzocaine, procaine, 2-aminothiazole and 4-amino-4H-1,2,4-triazole from polymer carriers (81) 103
- Komada, F., see Okumura, K. (88) 63
- Kontny, M.J., Koppenol, S. and Graham, E.T.  
Use of the sorption-desorption moisture transfer model to assess the utility of a desiccant in a solid product (84) 261
- Kopeček, J., see Říhová, B. (87) 105
- Kopečková, P., see Říhová, B. (87) 105
- Koppenol, S., see Kontny, M.J. (84) 261
- Kowalski, P., see Regosz, A. (88) 437
- Koyama, Y., see Nishikawa, M. (85) 75
- Koyama, Y., see Yamashita, F. (89) 199
- Kreuter, J., see Michel, C. (84) 93
- Kreuter, J., see Ruland, A. (85) 7
- Kristmundsdóttir, T., see Sveinsson, S.J. (82) 129
- Ktistis, G., see Attwood, D. (88) 417
- Kumakura, M., see Imasaka, K. (81) 31
- Kurihara-Bergstrom, T., see Liu, P. (90) 171
- Kurono, Y., Kato, S., Kuwayama, T., Tamaki, H., Hatano, K., Yashiro, T., Ikeda, K. and Bundgaard, H.  
*cis/trans* Isomerization and proton exchange reactions of 3,11b-dimethylbenzodiazepinooxazole (81) 179
- Kurosaki, Y., Nishimura, H., Terao, K., Nakayama, T. and Kimura, T.  
Existence of a specialized absorption mechanism for cefadroxil, an aminocephalosporin antibiotic, in the human oral cavity (82) 165
- Kurosaki, Y., see Araki, M. (81) 39
- Kurosaki, Y., see Noach, A.B.J. (90) 229
- Kuu, W.-Y.  
Determination of residence-time distribution in i.v. tubing of in-line drug delivery system using deconvolution technique (88) 369
- Kuwayama, T., see Kurono, Y. (81) 179
- Kwong, E., see Béchard, S.R. (87) 133
- Lahajnar, G., see Srčić, S. (87) 1
- Lai, W.F., see Wan, L.S.C. (81) 75
- Lam, S.Y., see Pershing, L.K. (86) 201
- La Manna, A., see Giunchedi, P. (85) 141
- La Manna, G., see Cavallaro, G. (90) 195
- Lambert, L.D., see Pershing, L.K. (86) 201
- Lanao, J.M., Vicente, M.T., Sayalero, M.L. and Domínguez-Gil, A.  
A method for the calculation of bioavailability in slow release formulations in the presence of within-individual variability (86) 123
- Larsen, R., see Bechgaard, E. (87) 125
- Larsen, R., see Bechgaard, E. (89) 147
- Laudanski, T., see Barnwell, S.G. (88) 423
- Laudanski, T., see Barnwell, S.G. (89) 245
- Laudanski, T., see Cole, S.K. (88) 211
- Law, D., see Khankari, R.K. (82) 117
- Law, M.Y.L., Pershing, L.K. and Roberts, L.K.  
Arecoline-induced skin inflammation: irritant or allergic dermatitis? (88) 251
- Law, S.L., Lo, W.Y., Lin, F.M. and Chaing, C.H.  
Dissolution and absorption of nifedipine in polyethylene glycol solid dispersion containing phosphatidylcholine (84) 161
- Layloff, T., see Shah, V.P. (82) 1
- Lechuga-Ballesteros, D., see Rodríguez-Hornedo, N. (85) 149
- Leclerc, B., see Husson, I. (86) 113
- Lee, M.G., see Jang, S.H. (84) 273
- Lee, M.G., see Kim, C.-K. (89) 91
- Lee, M.G., see Lee, S.H. (90) 81
- Lee, S.H., Yoon, W.H., Jang, S.H., Han, K.S., Jeong, K.-H., Kim, I.S. and Lee, M.G.  
Pharmacokinetics of a 22 kDa variant of unlabelled monomeric human growth hormone in rabbits (90) 81
- Lee, S.H., see Jang, S.H. (84) 273
- Legros, F.J., see Benameur, H. (89) 157
- Leharne, S.A., see Buckton, G. (83) 115
- Lerk, C.F., see Riepma, K.A. (85) 121
- Lerk, C.F., see Riepma, K.A. (87) 149
- Lerk, C.F., see Riepma, K.A. (90) R1
- Lerk, C.F., see Van der Veen, J. (87) 161

- Leroy, P., Gavriloff, C., Nicolas, A., Archimbault, P. and Ambroggi, G.  
Comparative assay of amoxicillin by high-performance liquid chromatography and microbiological methods for pharmacokinetic studies in calves (82) 157
- Leu, R. and Leuenberger, H.  
The application of percolation theory to the compaction of pharmaceutical powders (90) 213
- Leuenberger, H., see Leu, R. (90) 213
- Levy, G., see Peck, C.C. (82) 9
- Lherm, C., Müller, R.H., Puisieux, F. and Couvreur, P.  
Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length (84) 13
- Lherm, C., see Müller, R.H. (84) 1
- Li, L.C.  
In vitro controlled release of theophylline from tablets containing a silicone elastomer latex (87) 117
- Liaw, J. and Robinson, J.R.  
The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers (88) 125
- Liaw, J., Rojanasakul, Y. and Robinson, J.R.  
The effect of drug charge type and charge density on corneal transport (88) 111
- Lin, F.M., see Law, S.L. (84) 161
- Lindahl, L., see Engström, S. (86) 137
- Liu, C.-H., see Sheu, M.-T. (85) 57
- Liu, P., Nightingale, J.A.S. and Kurihara-Bergstrom, T.  
Variation of human skin permeation in vitro: Ionic vs neutral compounds (90) 171
- Li Wan Po, A., see Carstensen, J.T. (83) 87
- Li Wan Po, A., see Chan, S.Y. (83) 73
- Li Wan Po, A., see Wong, L.P. (83) 95
- Llabrés, M., see Sánchez, E. (83) 59
- Llabres, M., see Munguia, O. (86) 107
- Lo, W.Y., see Law, S.L. (84) 161
- Lootvoet, G., Beyssac, E., Shiu, G.K., Aiache, J.-M. and Ritschel, W.A.  
Study on the release of indomethacin from suppositories: in vitro-in vivo correlation (85) 113
- Lötter, A.P., see De Villiers, M.M. (88) 275
- Lötter, A.P., see Müller, D.G. (86) 175
- Love, W.G., see Williams, A.S. (85) 189
- Lucarelli, M., see Di Giulio, A. (89) 133
- Ludden, T., see Peck, C.C. (82) 9
- Lukowski, G., Müller, R.H., Müller, B.W. and Dittgen, M.  
Acrylic acid copolymer nanoparticles for drug delivery: I. Characterization of the surface properties relevant for in vivo organ distribution (84) 23
- Luyckx, M., see Faouzi, M.A. (89) 125
- Machida, Y., see Coutel-Egros, A. (84) 117
- Machida, Y., see Obata, Y. (89) 191
- Mackay, M., see Nicklin, P. (83) 197
- Magdassi, S., Royz, M. and Shoshan, S.  
Interactions between collagen and perfluorocarbon emulsions (88) 171
- Maggi, L., see Colombo, P. (88) 99
- Maggi, L., see Giunchedi, P. (85) 141
- Mahjour, M., see Senderoff, R.I. (83) 65
- Maincent, P., see Benoit, E. (84) 283
- Maitani, Y., see Coutel-Egros, A. (84) 117
- Maitani, Y., see Obata, Y. (89) 191
- Malick, A.W., see Seta, Y. (81) 89
- Mallevais, M.L., see Faouzi, M.A. (89) 125
- Mallinson, C.B., see Barnwell, S.G. (88) 423
- Mallon, C., see Attwood, D. (84) R5
- Mallon, C., see Attwood, D. (88) 417
- Manning, R.J. and Washington, C.  
Chemical stability of total parenteral nutrition mixtures (81) 1
- Margarit, M.V., Rodríguez, I.C. and Cerezo, A.  
Myrj 51 as a suppository excipient: Influence on pharmaceutical availability and bioavailability of sodium valproate (81) 67
- Margarit, M.V., see Fernández, M. (84) 197
- Marolt-Gomišček, M., see Sher, A. (90) 181
- Martin, F.J., see Woodle, M.C. (88) 327
- Masada, M., see Araki, M. (81) 39
- Mashimo, T., see Imasaka, K. (81) 31
- Massaccesi, M., see Scalia, S. (82) 179
- Mazzi, G., see Mulinacci, N. (90) 35
- McCafferty, D.F., see Woolfson, A.D. (84) 69
- McCarron, P.A., see Woolfson, A.D. (84) 69
- McCarthy, D.E., see Jani, P.U. (84) 245
- McCarthy, D.E., see Jani, P.U. (86) 239
- McCrossin, L.E., see Charman, W.N. (88) 397
- McDowall, R.D., see Shah, V.P. (82) 1
- McGilveray, I.J., see Shah, V.P. (82) 1
- McGloughlin, R.M.R. and Corrigan, O.I.  
Dissolution characteristics of benzoic acid-Tris mixtures (82) 135
- McKeown, R.H., see Prankerd, R.J. (83) 25
- McKeown, R.H., see Prankerd, R.J. (83) 39
- McNicol, K.J., see Schreier, H. (87) 183
- Medlicott, N.J., Jones, D.S., Tucker, I.G. and Holborow, D.  
Preliminary release studies of chlorhexidine (base and diacetate) from poly( $\epsilon$ -caprolactone) films prepared by solvent evaporation (84) 85
- Mehta, S.C., see Zingerman, J.P. (88) 303
- Melani, F., see Mulinacci, N. (90) 35
- Melia, C.D., see Watts, P.J. (87) 215
- Menegatti, E., see Nastruzzi, C. (90) 43
- Menon, G., see Adjei, A. (90) 141
- Mentrup, E., see Michel, C. (84) 93
- Meshali, M.M. and Gabr, K.E.  
Effect of interpolymer complex formation of chitosan with pectin or acacia on the release behaviour of chlorpromazine HCl (89) 177
- Mestiri, M., Puisieux, F. and Benoit, J.P.  
Preparation and characterization of cisplatin-loaded poly-methyl methacrylate microspheres (89) 229

- Michel, C., Purmann, T., Mentrup, E., Seiller, E. and Kreuter, J.  
Effect of liposomes on percutaneous penetration of lipophilic materials (84) 93
- Middaugh, C.R., see Burke, C.J. (86) 89
- Midha, K.K., see Shah, V.P. (82) 1
- Miller, E.S., see Hartauer, K.J. (85) 163
- Mitchell, A.G., see Dwivedi, S.K. (87) 95
- Mitchell, A.G., see Wong, M.W.Y. (88) 261
- Miyake, M., see Nakada, Y. (89) 169
- Miyata, N., see Kohri, N. (81) 49
- Miyazaki, K., see Kohri, N. (81) 49
- Miyazaki, M., see Morimoto, K. (81) 119
- Moelands, D., Karnik, N.A., Prankerd, R.J., Sloan, K.B., Stone, H.W. and Perrin, J.H.  
Microcalorimetric study of the interactions of aspartame with  $\beta$ -cyclodextrin and hydroxypropyl- $\beta$ -cyclodextrin: The anomalous heat of dilution of the latter (86) 263
- Moës, A.J., see Beten, D.B. (88) 31
- Moghimi, S.M., see Porter, C.J.H. (83) 273
- Montanari, C.A., see Montanari, M.L.C. (85) 199
- Montanari, M.L.C., Beezer, A.E., Sandal, J.B.P. and Montanari, C.A.  
Bioactivity of a series of substituted *N*-(3-phenyl-2-propenylidene)benzeneamines: a microcalorimetric study (85) 199
- Montenegro, L., see Bonina, F.P. (82) 171
- Montheard, J.P., see Kolli, M. (81) 103
- Morimoto, K., Iwakura, Y., Miyazaki, M. and Nakatani, E.  
Effects of proteolytic enzyme inhibitors of enhancement of transdermal iontophoretic delivery of vasopressin and an analogue in rats (81) 119
- Mørk, N., see Hansen, J. (81) 253
- Mortazavi, S.A., Carpenter, B.G. and Smart, J.D.  
An investigation of the rheological behaviour of the mucoadhesive/mucosal interface (83) 221
- Moschel, R.C., see Safadi, M. (90) 239
- Møss, J. and Bundgaard, H.  
Prodrugs of peptides. 17. Bioreversible derivatization of the C-terminal prolineamide residue in peptides to afford protection against prolyl endopeptidase (82) 91
- Muhuri, G., see Wan, L.S.C. (88) 159
- Mukherji, G. and Aggarwal, N.  
Quantitative estimation of salbutamol sulphate by derivative UV spectroscopy in the presence of albumin (86) 153
- Mulinacci, N., Melani, F., Mazzi, G. and Vincieri, F.F.  
Molecular modelling and NMR NOE experiments: Complementary tools for the investigation of complex ibuprofen- $\beta$ -cyclodextrin topology (90) 35
- Müller, B.W., see Lukowski, G. (84) 23
- Müller, B.W., see Waaler, P.J. (87) 223
- Müller, B.W., see Waaler, P.J. (87) 229
- Müller, B.W., see Wesemeyer, H. (89) 33
- Müller, D.G., Stella, V.J. and Lötter, A.P.  
The determination of the amphiphilic properties of a prodrug (DDMS) of phenytoin in aqueous media (86) 175
- Müller, R.H. and Wallis, K.H.  
Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908 (89) 25
- Müller, R.H., Lherm, C., Herbort, J., Blunk, T. and Couvreur, P.  
Alkylcyanoacrylate drug carriers: I. Physicochemical characterization of nanoparticles with different alkyl chain length (84) 1
- Müller, R.H., see Lherm, C. (84) 13
- Müller, R.H., see Lukowski, G. (84) 23
- Müller, R.H., see Wesemeyer, H. (89) 33
- Munguia, O., Delgado, A., Fariña, J., Evora, C. and Llabres, M.  
Optimization of dl-PLA molecular weight via the response surface method (86) 107
- Munro, S.L.A., see Charman, W.N. (88) 397
- Nada, A.H., see Etman, M.A. (88) 433
- Nada, A.H., see Hammouda, Y.E. (89) 111
- Nadai, T., see Araki, M. (81) 39
- Nagai, T., see Coutel-Egros, A. (84) 117
- Nagai, T., see Imasaka, K. (81) 31
- Nagai, T., see Obata, Y. (89) 191
- Nagasako, S., Hayashibara, M., Katagiri, Y. and Iwamoto, K.  
Effect of dose on salivary excretion of mexiletine after bolus intravenous administration in rats (81) 127
- Naik, A., Irwin, W.J. and Griffin, R.J.  
Percutaneous absorption of azidoprofen, a model for a soft anti-inflammatory drug for topical application (90) 129
- Naik, A., Irwin, W.J. and Griffin, R.J.  
The hydrolysis of azidoprofen esters: A model for a soft anti-inflammatory drug for topical application (89) 65
- Naik, A., Irwin, W.J. and Griffin, R.J.  
The reduction of azidoprofen: A model for a soft anti-inflammatory drug for topical application (89) 51
- Naik, A., see Watkinson, A.C. (87) 175
- Nair, M. and Chien, Y.W.  
Buccal delivery of progestational steroids: I. Characterization of barrier properties and effect of penetrant hydrophilicity (89) 41
- Nakada, Y., Miyake, M. and Awata, N.  
Some factors affecting the vaginal absorption of human calcitonin in rats (89) 169
- Nakahigashi, Y., see Ushirogawa, Y. (81) 133
- Nakamura, J., Kido, M., Nishida, K. and Sasaki, H.  
Hydrolysis of salicylic acid-tyrosine and salicylic acid-methionine prodrugs in the rabbit (87) 59
- Nakar, D., see Rubinstein, A. (84) 141
- Nakatani, E., see Morimoto, K. (81) 119
- Nakayama, T., see Araki, M. (81) 39
- Nakayama, T., see Kurosaki, Y. (82) 165
- Nam-Tran, H., see Ruelle, P. (87) 47
- Nannipieri, E., see Carelli, V. (88) 89
- Nannipieri, E., see Carelli, V. (89) 81

- Nastruzzi, C., Esposito, E., Pastesini, C., Gambari, R. and Menegatti, E.  
Comparative study on the release kinetics of methyl-nicotinate from topic formulations (90) 43
- Na'was, T.E., see Alkaysi, H.N. (87) 73
- Neau, S.H., Chafetz, L. and Chow, M.Y.  
Increasing the optical rotation of L-carbidopa by reaction with dicarbonyl compounds (82) 151
- Nelson, K.F., see Choudhury, S. (85) 175
- Newman, M.S., see Woodle, M.C. (88) 327
- Newton, J.M., see Baert, L. (86) 187
- Newton, J.M., see Fielden, K.E. (81) 205
- Newton, J.M., see Fielden, K.E. (81) 225
- Newton, J.M., see Odidi, I.O. (90) 203
- Newton, J.M., see Pinto, J.F. (83) 187
- Nguyen, N.T., see Kaul, D. (88) 345
- Nicklin, P., Irwin, B., Hassan, I., Williamson, I. and Mackay, M.  
Permeable support type influences the transport of compounds across Caco-2 cells (83) 197
- Nicolas, A., see Leroy, P. (82) 157
- Nielsen, V.F., see Pedersen, M. (90) 247
- Nightingale, J.A.S., see Liu, P. (90) 171
- Nishida, K., see Nakamura, J. (87) 59
- Nishikawa, M., Ohtsubo, Y., Ohno, J., Fujita, T., Koyama, Y., Yamashita, F., Hashida, M. and Sezaki, H.  
Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice (85) 75
- Nishimura, H., see Kurosaki, Y. (82) 165
- Nishimura, M., see Yamaguchi, T. (85) 87
- Nitta, K., see Ohwaki, T. (85) 19
- Niwa, T., see Kawashima, Y. (89) 9
- Niwa, T., see Ohwaki, T. (85) 19
- Niwa, T., see Takeuchi, H. (86) 25
- Nixon, P.R., see Sinko, C.M. (81) 243
- Noach, A.B.J., Kurosaki, Y., Blom-Roosemalen, M.C.M., De Boer, A.G. and Breimer, D.D.  
Cell-polarity dependent effect of chelation on the paracellular permeability of confluent Caco-2 cell monolayers (90) 229
- Nomura, A., see Kohri, N. (81) 49
- Norstedt, G., see Prisel, P.T. (85) 51
- Noszál, B., see Takács-Novák, K. (89) 261
- Nyström, C., see Angberg, M. (81) 153
- Nyström, C., see Angberg, M. (83) 11
- Nyström, C., see Angberg, M. (90) 19
- Nyström, C., see Sjökvist Saers, E. (90) 105
- Nyström, C., see Westerberg, M. (90) 1
- Obata, Y., Takayama, K., Maitani, Y., Machida, Y. and Nagai, T.  
Effect of ethanol on skin permeation of nonionized and ionized diclofenac (89) 191
- Odidi, I.O. and Newton, J.M.  
Cylindrical tube and surface tension viscous flow models in the assessment of capillary flow and liquid contact angles in pharmaceutical powders (90) 203
- Oh, D.-M., Sinko, P.J. and Amidon, G.L.  
Characterization of the oral absorption of several aminopenicillins: Determination of intrinsic membrane absorption parameters in the rat intestine in situ (85) 181
- Ohno, J., see Nishikawa, M. (85) 75
- Ohta, N., Yotsuyanagi, T., Chen, D., Ono, R., Ito, S. and Ikeda, K.  
Disulfide bond cleavage of human serum albumin and alterations of its secondary structure by *cis*-diammine-dichloroplatinum(II) (85) 39
- Ohtsubo, Y., see Nishikawa, M. (85) 75
- Ohwaki, T., Nitta, K., Ozawa, H., Kawashima, Y., Hino, T., Takeuchi, H. and Niwa, T.  
Improvement of the formation percentage of water-in-oil-in-water multiple emulsion by the addition of surfactants in the internal aqueous phase of the emulsion (85) 19
- Ohwaki, T., see Aoki, S. (85) 29
- Okamoto, R., see Yamaguchi, T. (85) 87
- Okumura, K., Iwakawa, S., Yoshida, T., Seki, T. and Komada, F.  
Intratracheal delivery of insulin. Absorption from solution and aerosol by rat lung (88) 63
- Olsen, C.E., see Jensen, J. (88) 177
- Ono, R., see Ohta, N. (85) 39
- Onur, M.A., Kirby, C.J., Isimer, A., Beksac, S., Basci, N., Pamir, R., Coskun, T. and Tumer, A.  
Effect of liposomal encapsulation of chloramphenicol on its transfer across the human placenta in a dual in vitro perfusion system (88) 313
- Opdebeeck, J.P., see Khan, M.Z.I. (90) 255
- Oratore, A., see Di Giulio, A. (89) 133
- Otagiri, M., see Suenaga, A. (82) 29
- Ozawa, H., see Aoki, S. (85) 29
- Ozawa, H., see Aoki, S. (85) 65
- Ozawa, H., see Ohwaki, T. (85) 19
- Ozawa, H., see Takeuchi, H. (86) 25
- Pagano, A., see Saettone, M.F. (86) 159
- Palazzo, S., see Cavallaro, G. (90) 195
- Pamir, R., see Onur, M.A. (88) 313
- Panderi, I. and Parissi-Poulou, M.  
Determination of captopril and captopril-hydrochlorothiazide combination in tablets by derivative UV spectrophotometry (86) 99
- Papadimitriou, E., Efentakis, M. and Choulis, N.H.  
Evaluation of maltodextrins as excipients for direct compression tablets and their influence on the rate of dissolution (86) 131
- Pardridge, W.M., see Terasaki, T. (81) 143
- Parissi-Poulou, M., see Panderi, I. (86) 99
- Paronen, P., see Tirkkonen, S. (88) 39
- Parsons, D.L., see Betageri, G.V. (81) 235
- Parsons, G.E., Buckton, G. and Chatham, S.M.  
The extent of the errors associated with contact angles obtained using liquid penetration experiments (82) 145
- Parsons, G.E., Buckton, G. and Chatham, S.M.  
The use of surface energy and polarity determinations to

- predict physical stability of non-polar, non-aqueous suspensions (83) 163
- Pastesini, C., see Nastruzzi, C. (90) 43
- Patel, J.M. and Wurster, D.E.  
Effect of hydrocarbon chain length on the hydrolysis of several naphthyl esters in the presence of *o*-iodosobenzoic acid and CTAB micelles (86) 43
- Pavanetto, F., Conti, B., Genta, I. and Giunchedi, P.  
Solvent evaporation, solvent extraction and spray drying for polylactide microsphere preparation (84) 151
- Peck, C.C., Barr, W.H., Benet, L.Z., Collins, J., Desjardins, R.E., Furst, D.E., Harter, J.G., Levy, G., Ludden, T., Rodman, J.H., Sanathanan, L., Schentag, J.J., Shah, V.P., Sheiner, L.B., Skelly, J.P., Stanski, D.R., Temple, R.J., Viswanathan, C.T., Weissinger, J. and Yacobi, A.  
Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development, *April 24–26, 1991, Arlington, VA* (82) 9
- Pedersen, M., Edelsten, M., Nielsen, V.F., Scarpellini, A., Skytte, S. and Slot, C.  
Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole (90) 247
- Pelplińska, T., see Regosz, A. (88) 437
- Pensé, A.M., Vauthier, C., Puisieux, F. and Benoit, J.P.  
Microencapsulation of benzalkonium chloride (81) 111
- Peppas, N.A., see Colombo, P. (88) 99
- Perrin, J.H., see Moelands, D. (86) 263
- Perrin, J.H., see Prankerd, R.J. (88) 189
- Pershing, L.K., Lambert, L.D., Shah, V.P. and Lam, S.Y.  
Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans (86) 201
- Pershing, L.K., see Law, M.Y.L. (88) 251
- Pinto, J.F., Buckton, G. and Newton, J.M.  
The influence of four selected processing and formulation factors on the production of spheres by extrusion and spheronisation (83) 187
- Pitarresi, G., see Cavallaro, G. (90) 195
- Pittman, K.A., see Shah, V.P. (82) 1
- Plazier-Vercammen, J.A.  
Investigation of the bioavailability of codeine from a cation ion-exchange sulfonic acid. 1. Effect of parameters (85) 45
- Plazier-Vercammen, J.A.  
Investigation of the bioavailability of codeine from a cation-exchange sulphonic acid. 2. Evaluation of release kinetics of codeine from the resinate and uptake of Na<sup>+</sup> from the solution (87) 31
- Plazonnet, B., see Thermes, F. (81) 59
- Po, A.L.W., see Jian, L. (86) 59
- Pochopin, N.L., see Charman, W.N. (88) 397
- Polack, A.E., see Donaldson, J.D. (88) 351
- Ponchel, G., see Irache, J.M. (90) R9
- Pop, E., Anderson, W., Vlasak, J., Brewster, M.E. and Bodor, N.  
Enhanced brain delivery of 2'-fluoro-5-methylarabinosyluracil (84) 39
- Porter, C.J.H., Moghimi, S.M., Davies, M.C., Davis, S.S. and Illum, L.  
Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow (83) 273
- Pourkavoos, N.  
Antimicrobial activity of cephaloridine in the presence of crude and purified preparations of bacterial  $\beta$ -lactamases before and after liposome encapsulation (82) 53
- Prankerd, R.J. and McKeown, R.H.  
Physico-chemical properties of barbituric acid derivatives. II: Partition coefficients of 5,5-disubstituted barbituric acids at 25°C (83) 25
- Prankerd, R.J. and McKeown, R.H.  
Physico-chemical properties of barbituric acid derivatives. III: Partition coefficients of cycloalkane-1',5-spirobarbituric acids at 25°C (83) 39
- Prankerd, R.J., Stone, H.W., Sloan, K.B. and Perrin, J.H.  
Degradation of aspartame in acidic aqueous media and its stabilization by complexation with cyclodextrins or modified cyclodextrins (88) 189
- Prankerd, R.J.  
Solid-state properties of drugs. I. Estimation of heat capacities for fusion and thermodynamic functions for solution from aqueous solubility-temperature dependence measurements (84) 233
- Prankerd, R.J., see Elsabee, M. (86) 211
- Prankerd, R.J., see Elsabee, M. (86) 221
- Prankerd, R.J., see Moelands, D. (86) 263
- Préat, V., see Tasset, C. (81) R5
- Price, J.H., see Woolfson, A.D. (84) 69
- Prisell, P.T., Camber, O., Hiselius, J. and Norstedt, G.  
Evaluation of hyaluronan as a vehicle for peptide growth factors (85) 51
- Pryce-Jones, R.H., Eccleston, G.M. and Abu-Bakar, B.B.  
Aminophylline suppository decomposition: an investigation using differential scanning calorimetry (86) 231
- Puglisi, G., see Castelli, F. (88) 1
- Puisieux, F., see Husson, I. (86) 113
- Puisieux, F., see Lherm, C. (84) 13
- Puisieux, F., see Mestiri, M. (89) 229
- Puisieux, F., see Pensé, A.M. (81) 111
- Puisieux, F., see Yu, W. (89) 139
- Purmann, T., see Michel, C. (84) 93
- Quigley, J.M., see Jordan, C.G.M. (84) 175
- Quraishi, O., see Béchar, S.R. (87) 133
- Rabasco, A.M., see Caraballo, I. (89) 213
- Radebaugh, G.W., see Senderoff, R.I. (83) 65
- Radebaugh, G.W., see Zingerman, J.P. (88) 303
- Radu, A., see Atanasiu, R. (90) 119
- Rajewski, L.G., Stinnett, A.A., Stella, V.J. and Topp, E.M.  
Enzymic and non-enzymic hydrolysis of a polymeric pro-drug: Hydrocortisone esters of hyaluronic acid (82) 205
- Rao, S., see Adjei, A. (90) 141

- Rao, S.S. and Ritschel, W.A.  
Development and in vitro/in vivo evaluation of a colonic release capsule of vasopressin (86) 35
- Rasmussen, S.N., see Hansen, L.B. (88) 243
- Rastelli, G., see Costantino, L. (86) 17
- Rathi, R.C., see Říhová, B. (87) 105
- Regosz, A., Pelplińska, T., Kowalski, P. and Thiel, Z.  
Prediction of solubility of sulfonamides in water and organic solvents based on the extended regular solution theory (88) 437
- Reig, F., see Colomé, C. (90) 59
- Rekkas, D.M., see Athanassiou, G.C. (85) 209
- Rekkas, D.M., see Athanassiou, G.C. (90) 51
- Rekkas, D.M., see Vlachou, M.D. (82) 47
- Remon, J.P., see Baert, L. (86) 187
- Remon, J.P., see De Muyck, C. (85) 103
- Rhodes, C.T., see Jiménez-Castellanos, M.R. (89) 223
- Richards, R.M.E. and Xing, D.K.L.  
Enhancement of antibacterial activity by *p*-aminobenzoic acid and sulphadiazine (82) 107
- Richards, R.M.E. and Xing, D.K.L.  
Investigation of the antibacterial activity of *p*-aminobenzoic acid against *P. aeruginosa* and *E. cloacae* (87) 195
- Richardson, J.L., Farraj, N.F. and Illum, L.  
Enhanced vaginal absorption of insulin in sheep using lysophosphatidylcholine and a bioadhesive microsphere delivery system (88) 319
- Richardson, M., see Fitzgerald, P. (83) 177
- Riepma, K.A., Dekker, B.G. and Lerk, C.F.  
The effect of moisture sorption on the strength and internal surface area of lactose tablets (87) 149
- Riepma, K.A., Dekker, B.G., Jager, R.S., Elberse, P.A. and Lerk, C.F.  
The effect of storage at ambient humidity on the BET-specific surface area of tablets compacted from different materials (90) R1
- Riepma, K.A., Zuurman, K., Bolhuis, G.K., De Boer, A.H. and Lerk, C.F.  
Consolidation and compaction of powder mixtures: III. Binary mixtures of different particle size fractions of different types of crystalline lactose (85) 121
- Říhová, B., Rathi, R.C., Kopečková, P. and Kopeček, J.  
In vitro bioadhesion of carbohydrate-containing *N*-(2-hydroxypropyl)methacrylamide copolymers to the GI tract of guinea pigs (87) 105
- Riley, C.M., see Ross, D.L. (83) 267
- Riley, C.M., see Ross, D.L. (87) 203
- Riley, C.M., see Ross, D.L. (88) 379
- Ritschel, W.A., see Lootvoet, G. (85) 113
- Ritschel, W.A., see Rao, S.S. (86) 35
- Roberts, L.K., see Law, M.Y.L. (88) 251
- Roberts, M.S., see Donaldson, J.D. (88) 351
- Roberts, R.J., see Rowe, R.C. (86) 49
- Robertson, J., see Cole, S.K. (88) 211
- Robinson, J., see Gandhi, R. (85) 129
- Robinson, J.R., see Dowty, M.E. (88) 293
- Robinson, J.R., see Liaw, J. (88) 111
- Robinson, J.R., see Liaw, J. (88) 125
- Rochira, M., see Ghezzi, E. (87) 21
- Rodman, J.H., see Peck, C.C. (82) 9
- Rodríguez-Hornedo, N., Lechuga-Ballesteros, D. and Wu, H.-J.  
Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals (85) 149
- Rodríguez, I.C., see Fernández, M. (84) 197
- Rodríguez, I.C., see Margarit, M.V. (81) 67
- Rodríguez, L., see Saettone, M.F. (86) 159
- Rohr, G., see Djordjevic, N.M. (81) 21
- Rojanasakul, Y., see Liaw, J. (88) 111
- Roland, M., see Tasset, C. (81) R5
- Ross, D.L. and Riley, C.M.  
Physicochemical properties of the fluoroquinolone antimicrobials. II. Acid ionization constants and their relationship to structure (83) 267
- Ross, D.L. and Riley, C.M.  
Physicochemical properties of the fluoroquinolone antimicrobials. III. Complexation of lomefloxacin with various metal ions and the effect of metal ion complexation on aqueous solubility (87) 203
- Ross, D.L., Elkinton, S.K. and Riley, C.M.  
Physicochemical properties of the fluoroquinolone antimicrobials. IV. 1-Octanol/water partition coefficients and their relationships to structure (88) 379
- Rowe, R.C. and Roberts, R.J.  
The effect of some formulation variables on crack propagation in pigmented tablet film coatings using computer simulation (86) 49
- Rowe, R.C.  
Molecular weight dependence of the properties of ethyl cellulose and hydroxypropyl methylcellulose films (88) 405
- Rowe, R.C., see Fielden, K.E. (81) 205
- Rowe, R.C., see Fielden, K.E. (81) 225
- Rowe, R.C., see Hancock, B.C. (83) 147
- Royz, M., see Magdassi, S. (88) 171
- Rozier, A., see Thermes, F. (81) 59
- Rubinstein, A., Nakar, D. and Sintov, A.  
Chondroitin sulfate: A potential biodegradable carrier for colon-specific drug delivery (84) 141
- Rubinstein, M.H., see Garr, J.S.M. (81) 187
- Rubinstein, M.H., see Garr, J.S.M. (82) 71
- Ruelle, P., Buchmann, M., Nam-Tran, H. and Kesselring, U.W.  
Comparison of the solubility of polycyclic aromatic hydrocarbons in non-associated and associated solvents: The hydrophobic effect (87) 47
- Ruland, A. and Kreuter, J.  
Influence of various penetration enhancers on the in vitro permeation of amino acids across hairless mouse skin (85) 7
- Rydén, L. and Edman, P.  
Effect of polymers and microspheres on the nasal absorption of insulin in rats (83) 1
- Ryoo, S.H., see Jang, S.H. (84) 273

- Saetone, M.F., Torracca, M.T., Pagano, A., Giannaccini, B., Rodriguez, L. and Cini, M.  
Controlled release of pilocarpine from coated polymeric ophthalmic inserts prepared by extrusion (86) 159
- Safadi, M., Bindra, D.S., Williams, T., Moschel, R.C. and Stella, V.J.  
Kinetics and mechanism of the acid-catalyzed hydrolysis of *O*<sup>6</sup>-benzylguanine (90) 239
- Sainz, M.C., Chantres, J.R., Elorza, B. and Elorza, M.A.  
DSC study of the action of phenylbutazone on DMPC and DPPC bilayers (89) 183
- Sakr, A., see Turkoglu, M. (88) 75
- Sakr, F.M.  
A new approach for insulin delivery via the pulmonary route: Design and pharmacokinetics in non-diabetic rabbits (86) 1
- Saletti, M.A., see Di Giulio, A. (89) 133
- Salomons-de Vries, M.A., see Bouwstra, J.A. (84) 205
- Salter, J.M., see Zingerman, J.P. (88) 303
- Samyn, C., see Van den Mooter, G. (87) 37
- Sanathanan, L., see Peck, C.C. (82) 9
- Sánchez, E., Evora, C.M. and Llabrés, M.  
Effect of humidity and packaging on the long-term aging of commercial sustained-release theophylline tablets (83) 59
- Sandal, J.B.P., see Montanari, M.L.C. (85) 199
- Sanghavi, N.M., see Choudhari, K.B. (89) 207
- Santi, P., see Catellani, P.L. (88) 285
- Sasaki, H., see Nakamura, J. (87) 59
- Sasaki, H., see Takeuchi, H. (86) 25
- Sattari, S., see Dwivedi, S.K. (87) 95
- Sawada, M., see Yamauchi, H. (90) 73
- Sayalero, M.L., see Lanao, J.M. (86) 123
- Scalia, S. and Massaccesi, M.  
Simultaneous determination of bendazac and underivatized lysine in ophthalmic preparations by reversed-phase ion-pair high-performance liquid chromatography (82) 179
- Scarpellini, A., see Pedersen, M. (90) 247
- Schaefer, H., see Shah, V.P. (82) 21
- Schentag, J.J., see Peck, C.C. (82) 9
- Schreiber, B., see Djordjevic, N.M. (81) 21
- Schreier, H., McNicol, K.J., Ausborn, M., Soucy, D.M., Derendorf, H., Stecenko, A.A. and Gonzalez-Rothi, R.J.  
Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep (87) 183
- Scott, D.C., Shah, R.D. and Augsburg, L.L.  
A comparative evaluation of the mechanical strength of sealed and unsealed hard gelatin capsules (84) 49
- Seijsener, C.B.J., see Kadir, F. (81) 193
- Seiller, E., see Michel, C. (84) 93
- Seki, T., see Okumura, K. (88) 63
- Senderoff, R.I., Mahjour, M. and Radebaugh, G.W.  
Characterization of adsorption behavior by solid dosage form excipients in formulation development (83) 65
- Serafini, M.F., see Carelli, V. (88) 89
- Serafini, M.F., see Carelli, V. (89) 81
- Seta, Y., Ghanem, A.H., Higuchi, W.I., Borsadia, S., Behl, C.R. and Malick, A.W.  
Physical model approach to understanding finite dose transport and uptake of hydrocortisone in hairless guinea-pig skin (81) 89
- Sezaki, H., see Nishikawa, M. (85) 75
- Sezaki, H., see Yamashita, F. (89) 199
- Shah, H.S., Tojo, K. and Chien, Y.W.  
Transdermal controlled delivery of verapamil: characterization of in vitro skin permeation (86) 167
- Shah, J.C., Chen, J.R. and Chow, D.  
Oral bioavailability and in situ absorption of etoposide in rat (84) 223
- Shah, J.C.  
Analysis of permeation data: evaluation of the lag time method (90) 161
- Shah, R.D., see Scott, D.C. (84) 49
- Shah, V.P., Behl, C.R., Flynn, G.L., Higuchi, W.I. and Schaefer, H.  
Principles and criteria in the development and optimization of topical therapeutic products, *March 26-28, 1990, Crystal City, VA* (82) 21
- Shah, V.P., Midha, K.K., Dighe, S., McGilveray, I.J., Skelly, J.P., Yacobi, A., Layloff, T., Viswanathan, C.T., Cook, C.E., McDowall, R.D., Pittman, K.A. and Spector, S.  
Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies, *December 3-5, 1990, Washington, DC* (82) 1
- Shah, V.P., see Brain, K.R. (89) R13
- Shah, V.P., see Peck, C.C. (82) 9
- Shah, V.P., see Pershing, L.K. (86) 201
- Shahjahan, M. and Enever, R.P.  
A stability-indicating assay for nitrofurazone by paper chromatography (82) 215
- Shahjahan, M. and Enever, R.P.  
Investigation of the nature of the interaction of nitrofurazone with urea (82) 229
- Shahjahan, M. and Enever, R.P.  
Some parameters for the solubilization of nitrofurazone and ultraviolet light absorbers by nonionic surfactants (82) 223
- Sheikh Salem, M., see Alkaysi, H.N. (87) 73
- Sheiner, L.B., see Peck, C.C. (82) 9
- Shek, P.N., see Jurima-Romet, M. (88) 201
- Shen, C.-C., see Tsai, T.-H. (84) 279
- Sher, A., Veber, M., Marolt-Gomišček, M. and Gomišček, S.  
Complexation of copper(II) ions with ampicillin. I: Spectroscopic and electrochemical investigation of interactions under equilibrium conditions (90) 181
- Sheu, M.-T., Chou, H.-L., Kao, C.-C., Liu, C.-H. and Sokoloski, T.D.  
Dissolution of diclofenac sodium from matrix tablets (85) 57
- Shim, C.-K. and Jung, B.-H.  
Inter- and intraindividual variations of multiple saliva peaks

- of acetaminophen after oral administration of tablets (82) 233
- Shim, C.-K. and Jung, B.-H.  
Noncontribution of enterohepatic recycling to multiple plasma peaks of acetaminophen in rats (83) 257
- Shiu, G.K., see Lootvoet, G. (85) 113
- Shoshan, S., see Magdassi, S. (88) 171
- Sidhu, D.S. and Sugden, J.K.  
Effect of food dyes on the photostability of aqueous solutions of L-ascorbic acid (83) 263
- Singh, A., see Singh, M. (85) R5
- Singh, M., Singh, O., Singh, A. and Talwar, G.P.  
Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres (85) R5
- Singh, O., see Singh, M. (85) R5
- Sinko, C.M., Smith, D.P. and Nixon, P.R.  
Mechanical characterization of hydroxypropyl methylcellulose: modulus determination from indentation loading profiles (81) 243
- Sinko, P.J., see Oh, D.-M. (85) 181
- Sintov, A., see Rubinstein, A. (84) 141
- Sizer, T., see Washington, C. (83) 227
- Sjökvist, E., see Aldén, M. (83) 47
- Sjökvist Saers, E. and Craig, D.Q.M.  
An investigation into the mechanisms of dissolution of alkyl *p*-aminobenzoates from polyethylene glycol solid dispersions (83) 211
- Sjökvist Saers, E., Nyström, C. and Aldén, M.  
Physicochemical aspects of drug release. XVI. The effect of storage on drug dissolution from solid dispersions and the influence of cooling rate and incorporation of surfactant (90) 105
- Sjöström, B. and Bergenståhl, B.  
Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate (88) 53
- Sjöström, B. and Bergenståhl, B.  
Preparation of submicron drug particles in lecithin-stabilized o/w emulsions: I. Model studies of the precipitation of cholesteryl acetate (84) 107
- Škalko, N., Čajkovic, M. and Jalšenjak, I.  
Liposomes with clindamycin hydrochloride in the therapy of *Acne vulgaris* (85) 97
- Skelly, J.P., see Peck, C.C. (82) 9
- Skelly, J.P., see Shah, V.P. (82) 1
- Skinner, M. and Kanfer, I.  
Intrinsic dissolution rate and solubility studies on josamycin, a macrolide antibiotic (88) 151
- Skytte, S., see Pedersen, M. (90) 247
- Slégel, P., see Valkó, K. (83) 123
- Sloan, K.B., see Moelands, D. (86) 263
- Sloan, K.B., see Pranker, R.J. (88) 189
- Slot, C., see Pedersen, M. (90) 247
- Smart, J.D., see Mortazavi, S.A. (83) 221
- Šmid-Korbar, J., see Kerč, J. (81) R1
- Šmid-Korbar, J., see Srčić, S. (87) 1
- Smistad, G., see Tønnesen, H.H. (90) 221
- Smith, D.P., see Sinko, C.M. (81) 243
- Sokoloski, T.D., see Sheu, M.-T. (85) 57
- Soucy, D.M., see Schreier, H. (87) 183
- Sparrow, R.A., see Wilding, I.R. (83) 155
- Sparrow, R.A., see Wilding, I.R. (84) 59
- Spector, S., see Shah, V.P. (82) 1
- Spenlehauer, G., see Husson, I. (86) 113
- Spiller, R.C., see Watts, P.J. (87) 215
- Srčić, S., Kerč, J., Urleb, U., Zupančič, I., Lahajnar, G., Kofler, B. and Šmid-Korbar, J.  
Investigation of felodipine polymorphism and its glassy state (87) 1
- Srčić, S., see Kerč, J. (81) R1
- Stanski, D.R., see Peck, C.C. (82) 9
- Steadman, B.L., see Burke, C.J. (86) 89
- Stecenko, A.A., see Schreier, H. (87) 183
- Steed, K.P., see Watts, P.J. (87) 215
- Stella, V.J., see Müller, D.G. (86) 175
- Stella, V.J., see Rajewski, L.G. (82) 205
- Stella, V.J., see Safadi, M. (90) 239
- Stinnett, A.A., see Rajewski, L.G. (82) 205
- Stone, H.W., see Moelands, D. (86) 263
- Stone, H.W., see Pranker, R.J. (88) 189
- Story, M.J., see Barnwell, S.G. (88) 423
- Story, M.J., see Barnwell, S.G. (89) 245
- Story, M.J., see Cole, S.K. (88) 211
- Ström, P., see Juppo, A.M. (88) 141
- Strom, R., see Di Giulio, A. (89) 133
- Sturesson, C., Carlfors, J., Edsman, K. and Andersson, M.  
Preparation of biodegradable poly(lactic-co-glycolic) acid microspheres and their in vitro release of timolol maleate (89) 235
- Suenaga, A., Bekers, O., Beijnen, J.H., Underberg, W.J.M., Tanimoto, T., Koizumi, K. and Otagiri, M.  
Stabilization of daunorubicin and 4-demethoxydaunorubicin on complexation with octakis(2,6-di-*O*-methyl)- $\gamma$ -cyclodextrin in acidic aqueous solution (82) 29
- Sugden, J.K., see Sidhu, D.S. (83) 263
- Sveinsson, S.J. and Kristmundsdóttir, T.  
Naproxen microcapsules: preparation and in vitro characterization (82) 129
- Swart, P.J., Toulouse, F.A.M. and De Zeeuw, R.A.  
The influence of azone on the transdermal penetration of the dopamine D<sub>2</sub> agonist N-0923 in freely moving rats (88) 165
- Swart, P.J., Weide, W.L. and De Zeeuw, R.A.  
In vitro penetration of the dopamine D<sub>2</sub> agonist N-0923 with and without Azone (87) 67
- Szász, G., see Takács-Novák, K. (89) 261
- Tabosa do Egito, E.S., see Yu, W. (89) 139
- Takács-Novák, K., Noszál, B., Tőkés-Kövesdi, M. and Szász, G.  
Acid-base properties and proton-speciation of vancomycin (89) 261
- Takada, K., see Ushirogawa, Y. (81) 133
- Takahashi, M., see Kohri, N. (81) 49



- Takayama, K., see Obata, Y. (89) 191
- Takechi, S., see Kohri, N. (81) 49
- Takeuchi, H., Sasaki, H., Niwa, T., Hino, T., Kawashima, Y., Uesugi, K. and Ozawa, H.  
Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion (86) 25
- Takeuchi, H., see Kawashima, Y. (89) 9
- Takeuchi, H., see Ohwaki, T. (85) 19
- Takeuchi, T., see Yamaguchi, T. (85) 87
- Talwar, G.P., see Singh, M. (85) R5
- Tamaki, H., see Kurono, Y. (81) 179
- Tanimoto, T., see Suenaga, A. (82) 29
- Tanninen, V.P. and Yliruusi, J.  
X-ray powder diffraction profile fitting in quantitative determination of two polymorphs from their powder mixture (81) 169
- Tasset, C., Pr at, V. and Roland, M.  
Comparison of the in vivo antifungal activity of amphotericin B-Solulan C24, amphotericin B-Myrj 59 and amphotericin B-Synperonic A50 with fungizone (81) R5
- Tatsuishi, K., see Aoki, S. (85) 29
- Tatsuishi, K., see Aoki, S. (85) 65
- Taylor, C.J., see Attwood, D. (84) R5
- Taylor, C.J., see Attwood, D. (88) 417
- Taylor, G., see Williams, A.S. (83) 233
- Taylor, G., see Williams, A.S. (87) 255
- Taylor, K.M.G., Venthoye, G. and Chawla, A.  
Pentamidine isethionate delivery from jet nebulisers (85) 203
- Tegenfeldt, J., see Ald n, M. (83) 47
- Temple, R.J., see Peck, C.C. (82) 9
- Terao, K., see Kurosaki, Y. (82) 165
- Terao, T., see Izutsu, K.-i. (90) 187
- Terasaki, T., Deguchi, Y., Kasama, Y., Pardridge, W.M. and Tsuji, A.  
Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis (81) 143
- Thermes, F., Rozier, A., Plazonnet, B. and Grove, J.  
Bioadhesion: The effect of polyacrylic acid on the ocular bioavailability of timolol (81) 59
- Thiel, Z., see Regosz, A. (88) 437
- Thomas, M., Kellaway, I.W. and Jones, B.E.  
A study by photon correlation spectroscopy of the influence of gelatin source, ionic strength and temperature on the gelation process (83) 139
- Thomas, M., see Durrani, A.M. (88) 409
- Timoney, R.F., see Jordan, C.G.M. (84) 175
- Tirkkonen, S. and Paronen, P.  
Enhancement of drug release from ethylcellulose microcapsules using solid sodium chloride in the wall (88) 39
- Tj rnelund, J., see Jensen, J. (88) 177
- Tojo, K., see Shah, H.S. (86) 167
- T k s-K vesdi, M., see Tak cs-Nov k, K. (89) 261
- Tomikawa, M., see Yamauchi, H. (90) 73
- T nnesen, H.H., Smistad, G.,  gren, T. and Karlsen, J.  
Studies on curcumin and curcuminoids. XXIII: Effects of curcumin on liposomal lipid peroxidation (90) 221
- Topp, E.M., see Rajewski, L.G. (82) 205
- Torracca, M.T., see Saettone, M.F. (86) 159
- Torrado, J.J., see Torrado, S. (86) 147
- Torrado, S., Torrado, J.J. and Cad rniga, R.  
Topical application of albumin microspheres containing vitamin A. Drug release and availability (86) 147
- T th, I., Del Olmo Fernandez, E., Hafeez, R.A., Holley, J.L., Wood, I.P., Ward, P. and Gibbons, W.A.  
Lipidic peptides. XII. Cellular uptake studies of a lipidic amino acid, its oligomers and highly lipophilic drug conjugates on Ehrlich ascites tumour cells (83) 131
- T th, I., see Valk , K. (83) 123
- Toth, I., see Del Olmo, E. (81) 267
- Toth, I., see Wood, I.P. (87) 141
- Toulouse, F.A.M., see Swart, P.J. (88) 165
- Tsai, P.-K., see Burke, C.J. (86) 89
- Tsai, T.-H., Shen, C.-C. and Chen, C.-F.  
Determination and UV spectral identification of 18 $\alpha$ -glycyrrhetic acid and 18 $\beta$ -glycyrrhetic acid for stability studies (84) 279
- Tsuji, A., see Terasaki, T. (81) 143
- Tucker, I.G., see Khan, M.Z.I. (90) 255
- Tucker, I.G., see Medlicott, N.J. (84) 85
- Tumer, A., see Onur, M.A. (88) 313
- Turco Liveri, V., see Cavallaro, G. (90) 195
- Turkoglu, M. and Sakr, A.  
Mathematical modelling and optimization of a rotary fluidized-bed coating process (88) 75
- Tushuizen, E., see Zanen, P. (81) 199
- Uekama, K., see Irie, T. (84) 129
- Uesugi, K., see Aoki, S. (85) 29
- Uesugi, K., see Aoki, S. (85) 65
- Uesugi, K., see Takeuchi, H. (86) 25
- Underberg, W.J.M., see Suenaga, A. (82) 29
- Underberg, W.J.M., see Van der Houwen, O.A.G.J. (89) R5
- Urleb, U., see Sr i , S. (87) 1
- Urtti, A., see Finne, U. (84) 217
- Ushirogawa, Y., Nakahigashi, Y., Kiriya, A. and Takada, K.  
Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats (81) 133
- Vadnere, M., see Adjei, A. (90) 141
- Valk , K., T th, I., Ward, P., Sl gel, P. and Gibbons, W.A.  
Lipidic peptides. XI. Quantitative structure-activity relationships of a series of lipidic amino acid conjugates of  $\beta$ -lactam antibiotics (83) 123
- Van Amerongen, I.A., De Ronde, H.A.G. and Klooster, N.T.M.  
Physical-chemical characterization of semisolid topical dosage form using a new dissolution system (86) 9

- Van den Mooter, G., Samyn, C. and Kinget, R.  
Azo polymers for colon-specific drug delivery (87) 37
- Van der Houwen, O.A.G.J., Bekers, O., Bult, A., Beijnen, J.H. and Underberg, W.J.M.  
Computation of mitomycin C- $\gamma$ -cyclodextrin complex stability constant (89) R5
- Van der Kolk, H., see Zanen, P. (81) 199
- Van der Spek, J.A., see Bouwstra, J.A. (84) 205
- Van der Veen, J., Buitendijk, H.H. and Lerk, C.F.  
Dissolution kinetics of ketanserine tartrate, the salt of a weakly basic drug (87) 161
- Van der Watt, J.G., see De Villiers, M.M. (88) 275
- Van Savage, G., see Yang, S.T. (86) 247
- Van Spiegel, P.I., see Zanen, P. (81) 199
- Van Vooren, J.P., see Benameur, H. (89) 157
- Vauthier, C., see Pensé, A.M. (81) 111
- Veber, M., see Sher, A. (90) 181
- Veiga, M.D., Bernad, M.J. and Escobar, C.  
Thermal behaviour of drugs from binary and ternary systems (89) 119
- Veillard, M., see Coutel-Egros, A. (84) 117
- Veillard, M., see Husson, I. (86) 113
- Venkataram, S., see Kaul, D. (88) 345
- Venthoye, G., see Taylor, K.M.G. (85) 203
- Ventura, C.A., see Castelli, F. (88) 1
- Vergnaud, J.M.  
Liquid transport controlled release processes in polymeric materials: Applications to oral dosage forms (90) 89
- Vergnaud, J.M., see Kolli, M. (81) 103
- Vicente, M.T., see Lanao, J.M. (86) 123
- Vincieri, F.F., see Mulinacci, N. (90) 35
- Viswanathan, C.T., see Peck, C.C. (82) 9
- Viswanathan, C.T., see Shah, V.P. (82) 1
- Vlachou, M.D., Rekkas, D.M., Dallas, P.P. and Choulis, N.H.  
Development and in vitro evaluation of griseofulvin gels using Franz diffusion cells (82) 47
- Vlasak, J., see Pop, E. (84) 39
- Volkin, D.B., see Burke, C.J. (86) 89
- Vrijhof, W.P., see Kok, W.J.J. (86) 259
- Waler, P.J. and Müller, B.W.  
Solid-phase extraction of naftidofuryl from human plasma for high-performance liquid chromatography analysis (87) 223
- Waler, P.J., Graffner, C. and Müller, B.W.  
Biopharmaceutical studies of naftidofuryl in hydrocolloid matrix tablets (87) 229
- Wakamatsu, K., see Irie, T. (84) 129
- Wallin, R., see Engström, S. (86) 137
- Wallis, K.H., see Müller, R.H. (89) 25
- Walters, K.A., see Ashton, P. (87) 261
- Walters, K.A., see Ashton, P. (87) 265
- Walters, K.A., see Brain, K.R. (89) R13
- Wan, L.S.C. and Lai, W.F.  
Multilayer drug-coated cores: A system for controlling drug release (81) 75
- Wan, L.S.C., Heng, P.W.S. and Muhuri, G.  
Incorporation and distribution of a low dose drug in granules (88) 159
- Ward, G.T., see Wilding, I.R. (83) 155
- Ward, P., see Tóth, I. (83) 131
- Ward, P., see Valkó, K. (83) 123
- Washington, C. and Sizer, T.  
Stability of TPN mixtures compounded from Lipofundin S and Aminoplex amino-acid solutions: Comparison of laser diffraction and Coulter counter droplet size analysis (83) 227
- Washington, C.  
The electrokinetic properties of phospholipid stabilized fat emulsions. VI. Zeta potentials of Intralipid 20% in TPN mixtures (87) 167
- Washington, C., see Davis, S.S. (82) 99
- Washington, C., see Manning, R.J. (81) 1
- Watkinson, A.C., Bunge, A.L. and Hadgraft, J.  
Aspects of the transdermal delivery of prostaglandins II (83) 171
- Watkinson, A.C., Bunge, A.L., Hadgraft, J. and Naik, A.  
Computer simulation of penetrant concentration-depth profiles in the stratum corneum (87) 175
- Watkinson, A.C., see Brain, K.R. (89) R13
- Watkinson, A.C., see Heard, C.M. (90) R5
- Watts, P.J., Barrow, L., Steed, K.P., Wilson, C.G., Spiller, R.C., Melia, C.D. and Davies, M.C.  
The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis (87) 215
- Weide, W.L., see Swart, P.J. (87) 67
- Weiss, J., see Yang, S.T. (86) 247
- Weissinger, J., see Peck, C.C. (82) 9
- Wesemeyer, H., Müller, B.W. and Müller, R.H.  
Adsorption of ethoxylated surfactants on nanoparticles. II. Determination of adsorption enthalpy by microcalorimetry (89) 33
- Westerberg, M. and Nyström, C.  
Physicochemical aspects of drug release. XVII. The effect of drug surface area coverage to carrier materials on drug dissolution from ordered mixtures (90) 1
- Wikberg, M. and Alderborn, G.  
Compression characteristics of granulated materials: VI. Pore size distributions, assessed by mercury penetration, of compacts of two lactose granulations with different fragmentation propensities (84) 191
- Wilding, I.R., Davis, S.S., Sparrow, R.A., Bloor, J.R., Hayes, G. and Ward, G.T.  
The effect of food on the in vivo behaviour of a novel sustained release formulation of tiaprofenic acid (83) 155
- Wilding, I.R., Sparrow, R.A., Davis, S.S. and Horton, R.J.  
The role of gastric emptying in the absorption and metabolism of nifedipine given in a modified release pellet formulation (84) 59
- Williams, A.C., Cornwell, P.A. and Barry, B.W.  
On the non-Gaussian distribution of human skin permeabilities (86) 69

- Williams, A.C., Edwards, H.G.M. and Barry, B.W.  
Fourier transform Raman spectroscopy. A novel application for examining human stratum corneum (81) R11
- Williams, A.S. and Taylor, G.  
Release of cromoglycate from dextran and inulin conjugates (87) 255
- Williams, A.S. and Taylor, G.  
Synthesis, characterization and release of cromoglycate from dextran conjugates (83) 233
- Williams, A.S., Love, W.G. and Williams, B.D.  
Synthesis of methotrexate-dimyristoylphosphatidylethanolamine analogs and characterization of methotrexate release in vitro (85) 189
- Williams, B.D., see Williams, A.S. (85) 189
- Williams, M.D., see Johnson, J.L. (90) 151
- Williams, T., see Safadi, M. (90) 239
- Williamson, I., see Nicklin, P. (83) 197
- Wilson, C.G., see Fitzgerald, P. (83) 177
- Wilson, C.G., see Watts, P.J. (87) 215
- Wolff, H.M., see Hadgraft, J. (89) R1
- Wong, L.P., Gilligan, C.A. and Li Wan Po, A.  
Preparation and characterisation of sustained-release ibuprofen-cetostearyl alcohol spheres (83) 95
- Wong, M.W.Y. and Mitchell, A.G.  
Physicochemical characterization of a phase change produced during the wet granulation of chlorpromazine hydrochloride and its effects on tableting (88) 261
- Wood, I.P., Toth, I., Holley, J.L. and Gibbons, W.A.  
Lipidic peptides. XIII: Synthesis, structure elucidation and in vitro toxicity assessment of chlorambucil conjugates with lipidic acids, lipidic amino acids and their oligomers (87) 141
- Wood, I.P., see Tóth, I. (83) 131
- Woodle, M.C., Newman, M.S. and Martin, F.J.  
Liposome leakage and blood circulation: Comparison of adsorbed block copolymers with covalent attachment of PEG (88) 327
- Woolfson, A.D., McCafferty, D.F., Gorman, S.P., McCarron, P.A. and Price, J.H.  
Design of an apparatus incorporating a linear variable differential transformer for the measurement of type III bioadhesion to cervical tissue (84) 69
- Wu, H.-J., see Rodríguez-Hornedo, N. (85) 149
- Wurster, D.E., see Patel, J.M. (86) 43
- Xing, D.K.L., see Richards, R.M.E. (82) 107
- Xing, D.K.L., see Richards, R.M.E. (87) 195
- Yachi, K., see Yamauchi, H. (90) 73
- Yacobi, A., see Peck, C.C. (82) 9
- Yacobi, A., see Shah, V.P. (82) 1
- Yamaguchi, T., Nishimura, M., Okamoto, R., Takeuchi, T. and Yamamoto, K.  
Glass formation of 4'-O-(4-methoxyphenyl)acetyltylosin and physicochemical stability of the amorphous solid (85) 87
- Yamamoto, K., see Yamaguchi, T. (85) 87
- Yamanaka, H., see Imasaka, K. (81) 31
- Yamashita, F., Koyama, Y., Sezaki, H. and Hashida, M.  
Estimation of a concentration profile of acyclovir in the skin after topical administration (89) 199
- Yamashita, F., see Nishikawa, M. (85) 75
- Yamashita, S., see Araki, M. (81) 39
- Yamauchi, H., Kikuchi, H., Yachi, K., Sawada, M., Tomikawa, M. and Hirota, S.  
Effects of glycoporphin and ganglioside GM<sub>3</sub> on the blood circulation and tissue distribution of liposomes in rats (90) 73
- Yang, S.T., Van Savage, G., Weiss, J. and Ghebre-Sellassie, I.  
The effect of spray mode and chamber geometry of fluid-bed coating equipment and other parameters on an aqueous-based ethylcellulose coating (86) 247
- Yashiro, T., see Kurono, Y. (81) 179
- Yliruusi, J., see Juppó, A.M. (88) 141
- Yliruusi, J., see Tanninen, V.P. (81) 169
- Yoon, W.H., see Lee, S.H. (90) 81
- York, P., see Hancock, B.C. (83) 147
- Yoshida, M., see Imasaka, K. (81) 31
- Yoshida, T., see Okumura, K. (88) 63
- Yoshioka, S., see Izutsu, K.-i. (90) 187
- Yotsuyanagi, T., see Ohta, N. (85) 39
- Yu, W., Tabosa do Egito, E.S., Barratt, G., Fessi, H., Devisaguet, J.P. and Puisieux, F.  
A novel approach to the preparation of injectable emulsions by a spontaneous emulsification process (89) 139
- Zanen, P., Van Spiegel, P.I., Van der Kolk, H., Tushuizen, E. and Enthoven, R.  
The effect of the inhalation flow on the performance of a dry powder inhalation system (81) 199
- Zia, H., see Jiménez-Castellanos, M.R. (89) 223
- Zingerman, J.P., Mehta, S.C., Salter, J.M. and Radebaugh, G.W.  
Validation of a computerized image analysis system for particle size determination. Pharmaceutical applications (88) 303
- Zuidema, J., see Kadir, F. (81) 193
- Zupančič, I., see Srčić, S. (87) 1
- Zuurman, K., see Riepma, K.A. (85) 121



## Subject Index

- Absorption, (82) 165; (84) 59; (84) 161; (84) 223; (85) 65; (85) 181; (87) 125; (88) 151; (88) 433; (89) 147; (90) 229
- Absorption enhancement, (88) 89
- Absorption enhancer, (81) 119
- Absorption rate constant, (81) 193
- Acacia, (89) 177
- Acetaminophen, (83) 257
- Acetaminophen tablet, (82) 233
- Acid-base equilibrium, (84) 33
- Acid-base mixture, (82) 135
- Acid-base properties, (89) 261
- Acid excipient, (84) 167
- Acidity constant, (84) R1; (88) 15; (89) 103
- Acid strength, (83) 39
- Acne vulgaris, (85) 97
- Acrolein nanoparticles, (90) 119
- Acrylic acid copolymer, (84) 23
- Acrylic copolymer, (86) 113
- Active transport, (88) 111
- Acute infection, (83) 251
- Acyclovir, (89) 199
- N*-Acylated prolineamide, (82) 91
- Adenocarcinoma cell line, (83) 197
- S*-Adenosylhomocysteine, (81) 267
- S*-Adenosylmethionine, (81) 267
- Adhesion-shear test, (89) 223
- Adhesive patch, (82) 39; (88) 391
- Adhesive strength measurement, (84) 69
- Adimensional number, (88) 99
- ADJ/PC6 plasmacytoma cell, (87) 141
- Administration set, (89) 125
- Adsorption, (81) 21; (83) 65; (83) 65; (88) 171; (88) 327; (89) 33
- Adsorption isotherm, (84) 283
- Adverse effects, (86) 59
- Aerosol, (85) 203
- Aging, (83) 59
- AIDS, (85) 203
- Albumin, egg, (85) 1
- Alkylcyanoacrylate nanoparticles, (84) 13
- Alkyl *p*-aminobenzoate, (83) 211
- Alkyl paraben, (90) 95
- Alprazolam, (88) 89
- Amaranth (E 123), (83) 263
- Amikacin, (87) 183
- Amino acid, (81) 1; (85) 7
- p*-Aminobenzoic acid activity, (87) 195
- Aminocephalosporin, (82) 165
- Aminoglycoside, (90) 59
- Aminopenicillin, (85) 181
- Aminophylline, (86) 231
- Aminopyrine, (81) 143
- 5-Aminosalicylic acid, (88) 177
- Aminotetralin, (87) 67; (88) 165
- Amorphization, (89) 207
- Amorphous solid, (85) 87
- Amoxicillin, (82) 157; (85) 181
- Amoxycillin, (86) 79
- Amphiphilic additive, (90) 187
- Amphotericin B, (81) R5; (89) 139
- Ampicillin, (82) 117; (85) 181; (90) 181
- Analysis, (82) 215; (86) 231
- Anhydrous digoxin, (82) 185; (82) 195
- Anhydrous lactose, (81) 153; (83) 11
- Anhydrous theophylline, (85) 149
- Antarox, (89) 33
- Antazoline, (86) 59
- Antibacterial activity, (83) 123; (87) 195
- Antibacterial combination, (82) 107
- Antibiotic, (88) 151; (90) 181
- Antibody response, (90) 255
- Antibody titer, (85) R5
- Antifungal activity, (81) R5
- Antigen, (88) 335
- Antigen delivery, (90) 255
- Anti-inflammatory drug, (88) 1
- Antimicrobial, (83) 267; (87) 203; (88) 379
- Antimicrobial activity, (87) 73
- Antimycotic effect, (90) 247
- Anti-psoriatic agent, (89) 51
- Antipyrene, (81) 143
- Aqueous coating, (86) 247
- Aqueous ophthalmic solution, determination, (82) 179
- Aqueous polymer dispersion, (88) 75
- Aqueous solution, (90) 19
- Arecoline, (88) 251
- Arginine-vasopressin, (86) 35
- Arthritis, (85) 189
- Artificial membrane, (86) 9
- Ascorbic acid, (88) 39; (90) 19
- L*-Ascorbic acid, (83) 263
- Aspartame, (86) 263; (88) 189
- Associative species, (86) 175

- Atenolol, (81) 235; (89) 245  
 Availability, (81) 193  
 Axial dispersion model, (88) 369  
 Azide reduction, (89) 51  
 Azidoprofen, (89) 65; (90) 129  
 Azone, (82) 39; (87) 67; (88) 165  
 Azone<sup>®</sup>, (85) 7  
 Azo polymer, (87) 37  
 Azo reduction, (87) 37
- Bacterial uptake, (87) 195  
 Banding, (84) 49  
 Barbiturate, (83) 25; (83) 39  
 Barrier characterization, (89) 41  
 Basic drug, (85) 141  
 Bendazac lysine, (82) 179  
 Benzalkonium chloride, (81) 111  
 Benzoic acid, (82) 135  
*O*<sup>6</sup>-Benzylguanine, (90) 239  
 Betaxolol chlorhydrate, (84) 283  
 Bethe lattice, (90) 213  
 BET isotherm, (81) 21  
 Bile acid, (89) 81; (89) 245  
 Bile salt, (84) 107; (88) 53; (88) 125  
 Binary compact, (90) 151  
 Binary system, (89) 119  
 Binding constant, (86) 263  
 Bioactivity, (85) 199  
 Bioadhesion, (81) 59; (83) 221; (84) 69; (87) 105; (88) 409; (89) 223  
 Bioadhesive, (82) 61  
 Bioadhesive microspheres, (88) 319  
 Bioadhesive polymer, (87) 105  
 Bioavailability, (81) 49; (81) 67; (84) 223; (84) 273; (85) 175; (85) 209; (86) 1; (86) 123; (87) 229; (88) 63; (88) 165; (89) 9; (89) 75  
 Bioavailability studies, (86) 79  
 Biodegradable coating, (87) 37  
 Biodegradable implant, (89) 251  
 Biodegradable lipid implant, (90) 255  
 Biodegradable polymer, (81) 31; (84) 151  
 Biodegradation, (84) 141; (89) 235  
 Bioequivalence, (86) 201  
 Biological factors, (86) 167  
 Biopolymer, (87) 21  
 Biorheology, (83) 221  
 Birefringence, (87) 265  
 Blastospore, (84) 77; (86) 193  
 Block copolymer, (88) 327  
 Blood-brain barrier, (84) 39  
 Blood total leucocyte count, (81) 133  
 Bone marrow, (83) 273  
 Bottom spray, (86) 247  
 Bovine albumin, (86) 153  
 Box-Behnken design, (88) 75  
 Brain interstitial fluid, (81) 143  
 Brain microdialysis, (81) 143  
 Brain-specific delivery, (84) 39  
 Brattleboro rat, (86) 35  
 Brittleness, (84) 49  
 Bronchoalveolar lavage fluid, (88) 201  
 Bropirimine, (83) 241  
 Buccal absorption, (84) 117; (88) 237; (88) 243  
 Buccal delivery, (85) 129; (88) 221; (88) 229; (89) 41  
 Budesonide, (86) 9  
 Buffer capacity, (83) 241  
 Buffer index, (87) 11  
 Bupivacaine, (84) 33  
 Burst effect, (84) 85
- Caco-2, (83) 197  
 Caffeine, (81) 143; (82) 117  
 Calorimetry, (83) 115  
*Candida albicans*, (81) R5; (84) 77; (86) 193  
 Capillary endothelium, (90) 119  
 Capping pressure, (81) 187  
 Capsules, (87) 89  
 Captopril, (86) 99  
 Captopril-hydrochlorothiazide combination tablet, (86) 99  
 Carbamate, (81) 253  
 Carbamazepine, (82) 67; (82) 117; (85) 175  
 L-Carbidopa, (82) 151  
 Carbolpol, (88) 409  
 Carbolpol 934P, (83) 221  
 $\beta$ -Carotene, (88) 211  
 Cationic antimicrobial agent, (84) 77; (86) 193  
 Cefadroxil, (82) 165  
 Cell culture, (84) 13  
 Cellophane membrane, (89) 111  
 Cell permeability, (87) 195  
 Cell-polarity, (90) 229  
 Cellular uptake, (83) 131  
 Cellulitis, (90) 43  
 Cellulose acetate phthalate, (86) 35; (87) 239  
 Centrifugal force, (88) 285  
 Cephalexin, (82) 165  
 Cephaloridine, (82) 53  
 Cervical tissue, (84) 69  
 Cetosteryl alcohol sphere, (83) 95  
 Cetyltrimethylammonium bromide, (86) 43  
 Chamber geometry, (86) 247  
 Charge density, (88) 111  
 Charge reversal, (82) 99  
 Charge type, (88) 111  
 Checkerboard MIC determination, (82) 107  
 Chelating agent, (90) 221  
 Chemically modified cyclodextrin, (84) 129  
 Chemotherapy, (83) 251  
 Chiral drug, (86) 211; (86) 221  
 Chiral purity, (86) 221  
 Chitosan, (88) 9; (89) 1; (89) 19; (89) 177  
 Chitosonium malate, (89) 19  
 Chlorambucil, (87) 141  
 Chloramphenicol, (88) 313

- Chlorhexidine, (84) 85  
 Chlorpheniramine maleate, (88) 159  
 Chlorpromazine hydrochloride, (88) 261  
 Cholesterol, (90) 255  
 Cholesterol biosynthesis inhibitor, (89) 133  
 Cholesteryl acetate, (84) 107; (88) 53  
 Chondroitin sulfate, (84) 141  
 Chronic infection, (83) 251  
 Ciliotoxicity, (86) 59  
 Circular dichroism, (85) 39  
 Cisplatin, (89) 229  
 Clearing transcytosis, (90) 119  
 Clindamycin hydrochloride, (85) 97  
 Clotrimazole tablet, (88) 9  
 Coacervation, (82) 129  
 Codeine resinate, (85) 45; (87) 31  
 Cogrounding, (89) 207  
 Collagen, (88) 171  
 Colloidal carrier, (86) 239  
 Colloidal gold, (90) 119  
 Colloidal particle uptake, (84) 245  
 Colon, (84) 141  
 Colonic delivery, (84) 141  
 Colonic release capsule, (86) 35  
 Colon targeting, (87) 37  
 Colon transit, (87) 215  
 Compact, (81) 243  
 Compaction, (84) 191; (85) 121  
 Compartment, (88) 351  
 Compatibility, (89) 125  
 Complex, (89) 177  
 Complexation, (82) 229; (88) 189  
 Compression, (81) 243; (88) 285  
 Compression speed, (81) 187; (82) 71; (89) R17  
 Computer-controlled drug release, (87) 89  
 Computer simulation, (87) 175  
 Concentration/depth profiles, (87) 175  
 Concomitant administration, (89) 75  
 Conductivity, (86) 175  
 Conformational analysis, (89) 157  
 Conjugate, (83) 233; (85) 189; (87) 255  
 Consolidation, (85) 121  
 Contact angle, (82) 145; (84) 23; (90) 203  
 Controlled drug delivery, (81) 103  
 Controlled release, (85) R1; (86) 159; (87) 117; (88) 31; (88) 99; (88) 201  
 Controlled release suspension, (89) 9  
 Controlled-release tablet, (83) 59  
 Convolution integral, (88) 369  
 Cooling rate, (90) 105  
 Coordination compound, (90) 181  
 Copper, (90) 181  
 Coprecipitation, (88) 345  
 Corneal absorption, (88) 125  
 Coulometric Karl Fischer moisture determinations, (82) 185  
 Crack propagation, (86) 49  
 Cream, (82) 39; (86) 147  
 Critical micelle concentration, (83) 53  
 Critical micelle temperature, (83) 53  
 Cromoglycate, (83) 233; (87) 255  
 Croscarmellose sodium, (83) 65  
 Crushing strength, (81) 187; (82) 71  
 Crystal habit, (88) 345  
 Crystallization, (85) 149  
 C5-substituent  $\alpha$ -chain branching, (83) 25  
 Cubic phase, (86) 137  
 Curcumin, (87) 79; (90) 221  
 Cyanoacrylate nanoparticle, (84) 1  
 Cyclacillin, (85) 181  
 Cycloalkane spiro group, (83) 39  
 Cyclodextrin, (88) 189  
 $\beta$ -Cyclodextrin, (85) 1; (86) 263; (90) 35; (90) 247  
 Cyclosporin A, (81) 21; (82) 79; (82) 85  
 Cylinder extruder, (81) 225  
 Cylindrical tube model, (90) 203  
 Cytochalasin B, (88) 125  
 Cytotoxicity, (84) 13; (87) 141  
  
 Data variation, (90) 171  
 Daunorubicin, (82) 29  
 Deacetylated chitin, (88) 9; (89) 1  
 1-Deamino-8-arginine vasopressin, (81) 119  
 Decomposition, (86) 231  
 Deconvolution, (86) 211; (86) 221  
 Deconvolution integral, (88) 369  
*n*-Decylmethyl sulfoxide, (88) 391  
 Deformation hardness, (90) 213  
 Degradation, (82) 29; (84) 13; (88) 189; (88) 275; (89) 169  
 Degradation product, (88) 177  
 Dehydration-rehydration vesicle, (88) 313  
 Delivery, (88) 63  
 4-Demethoxydaunorubicin, (82) 29  
 Derivative spectrophotometry, (89) 133  
 Derivative UV analysis, (86) 153  
 Derivative UV spectrophotometry, (86) 99  
 Desferoxamine, (88) 327  
 Desiccant, (84) 261  
 Dexamethasone, (89) 157  
 Dexamethasone palmitate, (89) 157  
 Dextran, (83) 233; (87) 255  
 Dextrose, (88) 141  
 Diabetes, (86) 1  
 Diacid base, (89) 103  
 Dialysis clearance, (81) 143  
 Dialysis rotating cell, (85) 113  
 Dialysis test, (85) 19  
*cis*-Diamminedichloroplatinum(II), (85) 39  
 Diazepam, (89) 139; (89) 207  
 Dibasic acid, (89) 103  
 Dibasic calcium phosphate, (82) 71  
 Diclofenac, (89) 191  
 Diclofenac sodium, (85) 57  
 Didecanoyl-*L*- $\alpha$ -phosphatidylcholine, (89) 147  
 Die diameter, (81) 225

- Dielectric constant, (88) 437  
 Dielectric measurement, (84) 283  
 Dietary protein, (81) 133  
 Diffraction pattern, (81) 169  
 Diffraction profile, (81) 169  
 Diffuse reflectance, (85) 163  
 Diffuse reflectance Fourier transform infrared spectroscopy, (82) 195  
 Diffusion, (88) 351; (90) 95; (90) 161  
 Diffusion coefficient, (90) 161  
 Diffusion layer, (88) 151  
 Diffusion model, (86) 9; (89) 199  
 Diffusivity, (87) 31  
 Digitonin, (88) 125  
 Digoxin ·  $\frac{1}{2}$ H<sub>2</sub>O, (82) 185  
 Digoxin ·  $\frac{1}{4}$ H<sub>2</sub>O, (82) 185  
 Digoxin ·  $\frac{1}{2}$ H<sub>2</sub>O, (82) 195  
 Digoxin ·  $\frac{1}{4}$ H<sub>2</sub>O, (82) 195  
 Digoxin hydrate, (82) 185  
 1,3-Diketone, (87) 79  
 Diketopiperazine, (88) 189  
 Dimethylbenzodiazepinooxazole, (81) 179  
 Diphenhydramine · HCl, (81) 75  
*gem*-Diphenyl, (83) 25  
 Dipyrindamole, (81) 49; (88) 31  
 Direct compression, (86) 131; (87) 117  
 Directly compressible tablets, (89) 19  
 Direct tableting ability, (88) 9; (89) 1  
 Disintegrating tablet, (89) 1  
 Dispersion coefficient, (88) 369  
 Dissolution, (81) 75; (83) 187; (84) 161; (85) 29; (85) 149; (85) R1; (86) 131; (88) 31  
 Dissolution enhancement, (89) 207  
 Dissolution, in vitro, (85) 65  
 Dissolution kinetics, (87) 161  
 Dissolution mechanism, (82) 135; (84) 167  
 Dissolution profile, (85) 1  
 Dissolution rate, (83) 59; (83) 211; (84) 223; (85) 175; (90) 1; (90) 105  
 Dissolution testing, (86) 79; (88) 23  
 Distribution coefficient, (84) 175  
 Disulfide bond, (85) 39  
 Dithiosalicylic acid, (89) 213  
 Dopamine agonist, (88) 165  
 Dopamine D2 agonist, (87) 67  
 Dose dependence, (81) 127  
 Dose-dependent pharmacokinetics, (90) 81  
 Dose-independent pharmacokinetics, (84) 273  
 Doxorubicin, (89) R9  
 Drug delivery, (84) 141; (87) 21; (88) 201; (88) 423  
 Drug delivery system, (81) 31; (89) 133; (90) 73  
 Drug dissolution, (90) 151  
 Drug formulation, (86) 259  
 Drug permeability, (81) 39  
 Drug pumps, (87) 89  
 Drug release, (86) 147; (88) 39; (89) 177; (89) 235; (90) 1  
 Drug release rate, (89) 9  
 Drug stability, (88) 9  
 Drug targeting, (85) 75; (90) 119  
 Dry emulsion, (86) 25  
 Dry powder inhaler, (81) 199  
 DSC, (81) 153; (82) 117; (82) 185; (83) 11; (83) 95; (84) 197; (85) 103; (86) 211; (86) 221; (86) 231; (87) 1; (87) 265; (88) 1; (89) 119; (89) 183; (90) 105  
 Dye solubilization, (83) 53  
 Dynamic light scattering, (86) 175  
 Dynamic testing, (83) 241  
 Econazole, (90) 247  
 EDTA, Caco-2 cell line, (90) 229  
 Efflux, (88) 327  
 Ehrlich ascites tumour cell, (83) 131  
 Electrical resistance, (81) 39; (85) 129  
 Electrolyte, (81) 1  
 Electrophoretic mobility, (88) 171  
 ELISA, (85) R5  
 Emulsion, (81) 111; (83) 227; (84) 107; (86) 25; (87) 167; (88) 53  
 Emulsion stability, (89) 139  
 Emulsion, w/o/w, (85) 19  
 Enantiomer, (87) 95; (90) R5  
 Enantioselective transfer, (90) R5  
 Enhancement factor, (82) 171  
 Enhancer, (90) 129; (90) 229  
 Enteric-coated liquid-filled hard gelatin capsules, (88) 423  
 Enterohepatic recycling, (83) 257  
 Enthalpy, (89) 33  
 Enthalpy of dehydration, (82) 117  
 Enthalpy of fusion, (86) 211; (86) 221  
 Enthalpy of vaporization, (82) 117  
 Entropy, (89) 33  
 Enzymatic hydrolysis, (82) 91  
 Enzyme inhibition, Inhibition constants, (86) 17  
 Enzyme-mediated transesterification, (89) 65  
 Enzymic hydrolysis, (88) 221  
 Epitaxy, (85) 149  
 Ester, (88) 229  
 Esterase, (82) 205; (85) 189; (87) 255  
 Estradiol, (86) 69  
 Estradiol-17 $\beta$ , (89) 251  
 Estramustine, (81) 31  
 Ethanol, (81) R1; (89) 191  
 Ethyl cellulose, (82) 129  
 Ethylcellulose, (85) 29; (87) 247; (88) 39  
 Ethylenediamine, (86) 231  
*N,N'*-Ethylenediyl bishexadecanamide, (86) 231  
 Etoposide, (84) 223  
 Eudragit<sup>®</sup> NE 30 D, (86) 35  
 Eudragit RL, (81) 103  
 Eudragit RL100, (85) R1; (86) 159; (88) 31  
 Eudragit RS, (86) 159  
 Eudragit<sup>™</sup> S100, (86) 35  
 Eudragit S, (88) 31  
 Eutectic, (83) 95



- Excipient, (89) 1
- Excised human skin, (82) 171
- Exponentially modified Gaussian distribution, (86) 211
- Extended drug release, (85) 141
- Extended release, (87) 229
- Extrusion, (83) 187; (86) 187
- Extrusion force, (86) 187
- Extrusion/spheronization, (81) 205; (81) 225
- Factorial design, (88) 23
- Factorial experiment, (86) 59
- Fat base composition, (85) 103
- Fat emulsion, (82) 99; (89) 139
- Fatty base, (89) 111
- Feed system, (88) 285
- Felodipine, (81) R1; (87) 1
- Fe<sup>3+</sup> reduction, (87) 79
- Fibrin film, (90) 95
- Fick's laws of diffusion, (90) 161
- Film coating, (86) 49; (88) 405
- Film properties, (88) 405
- Finite dose, (81) 89
- First-pass metabolism, (81) 253
- Flavonol stability, (86) 17
- Flip-flop model, (84) 223
- Flowability, (85) 29
- Flow testing, (83) 241
- Flow-through cell, (85) 113
- Flow through method, (88) 23
- Fluidised bed granulation, (88) 159
- Fluidized bed, (86) 247
- Fluidized-bed coating, (81) 75
- Fluid sealing, (84) 49
- 2'-Fluoro-5-methylarabinosyluracil, (84) 39
- Fluoroquinolone, (83) 267; (87) 203; (88) 379; (89) 125
- 5-Fluorouracil, (86) 69
- Flurbiprofen, (85) R1
- Flux, (90) 161
- Food effect, (89) 245
- Food intake, (82) 233
- Force of failure, (84) 49
- Formation percentage, (85) 19
- Formulation, (83) 187; (84) 261
- Fourier transform infrared spectroscopy, (85) 163; (87) 1
- Fracture, (86) 49
- Fragility, (84) 49
- Franz diffusion cell, (82) 47
- Free energy change, (86) 43
- Freeze-drying, (90) 187
- Furosemide, (88) 275; (89) 19
- <sup>67</sup>Ga, (88) 327
- β-Galactosidase, (90) 187
- Gamma scintigraphy, (82) 99; (83) 177; (84) 59; (87) 215
- Ganglioside GM<sub>3</sub>, (90) 73
- Gastric acidity, (81) 49
- Gastric-acidity-controlled rabbit, (81) 49
- Gastric emptying, (88) 433
- Gastric liquid, (81) 103
- Gastrointestinal epithelium, (83) 197
- Gastrointestinal transit, (83) 155; (84) 59
- Gaussian distribution, (86) 69; (86) 211
- Gelatin, water-soluble, (85) 1
- Gelation, (83) 139
- Gel chromatography, (83) 233
- Glass transition temperature, (85) 87
- Glassy state, (85) 87; (87) 1
- Glucose, (81) 1; (88) 141
- L-Glutamic acid, (88) 111
- Glutathione, (88) 201
- Glycerol monooleate, (86) 137
- Glycophorin, (90) 73
- Glycosylated albumin, (85) 75
- 18α-Glycyrrhetic acid, (84) 279
- 18β-Glycyrrhetic acid, (84) 279
- GPC, (86) 107
- Granulation, (88) 141
- Granule fragmentation, (84) 191
- Granule size, (88) 141
- Gravimetry, (90) R9
- Gravity feed extruder, (86) 187
- Green S (E 142), (83) 263
- Grinding, (86) 221
- Griseofulvin, (83) 47; (90) 1; (90) 105
- Griseofulvin gel, (82) 47
- Griseofulvin/PEG 6000/Tween 20, (89) 119
- Growth promotion, (89) 251
- Guinea pig intestine, (87) 105
- Gut homogenate, (82) 91
- Habit modification, (88) 345
- Hairless guinea-pig skin, (81) 89
- Hairless mouse skin, (85) 7; (86) 167; (88) 89; (89) 81
- Half-life, (88) 189
- Hamster cheek pouch, (82) 165
- Hard gelatin capsule, (84) 49
- Hard gelatin capsules, (88) 211
- Heat capacity, (84) 233
- Heat of dilution, (86) 263
- Heckel equation, (90) 213
- α-Helix, (85) 39
- Hemihydrate, (88) 261
- Heparin sodium salt, (82) 171
- Heteroalkyl amino acid, (81) 267
- High-sensitivity DSC, (83) 115
- High solubility, (86) 263
- Hildebrand approach, (88) 437
- Hill coefficient, (88) 111
- Hot-stage microscopy, (89) 119
- HPLC, (82) 157; (83) 233; (84) 279; (85) 189; (87) 223; (89) 125; (90) 19
- HPLC assay, (87) 195
- HPMC, (82) 145
- rHuIFN-αA, (84) 273

- Human, (82) 165  
 Human cadaver skin, (88) 391; (90) 171  
 Human calcitonin, (89) 169  
 Human growth hormone variant, (90) 81  
 Human placenta, (88) 313  
 Human plasma, (87) 223  
 Human serum albumin, (85) 39  
 Human skin, (81) R11; (86) 69; (86) 201; (87) 261  
 Human subject, (81) 49  
 Hyaluronan, (85) 51  
 Hyaluronic acid, (82) 205  
 Hyaluronidase, (82) 205  
 Hyauronane, (87) 21  
 Hydrate, (82) 117  
 Hydration, (81) 153; (83) 11; (84) 205  
 Hydrochlorothiazide, (86) 99  
 Hydrocolloid matrix tablet, (87) 229  
 Hydrocortisone, (82) 205  
 Hydrocortisone transport, (81) 89  
 Hydrocortisone uptake, (81) 89  
 Hydrolysis, (81) 253; (82) 205; (83) 233; (84) 175; (85) 189; (86) 43; (87) 59; (87) 255; (88) 189; (89) 65; (90) 239  
 Hydrophilic albumin microspheres, (89) 91  
 Hydrophilicity effect, (89) 41  
 Hydrophilic-lipophilic balance, (81) 111  
 Hydrophilic matrix, (85) 57; (85) 141  
 Hydrophilic polymer, (89) 223  
 Hydrophilic system, (88) 99  
 Hydrophobic effect, (87) 47  
 Hydrophobic interaction chromatography (HIC), (84) 23  
 Hydrotropic activity, (83) 53  
 Hydroxyapatite, (86) 137  
 Hydroxyl radical, (87) 79  
 2-Hydroxypropyl- $\beta$ -cyclodextrin, (85) 175  
 Hydroxypropyl- $\beta$ -cyclodextrin, (86) 263; (90) 187; (90) 247  
 Hydroxypropyl cellulose, (82) 61  
 Hydroxypropylcellulose, (85) 29  
 Hydroxypropyl cellulose, (90) 151  
*N*-(2-Hydroxypropyl)methacrylamide copolymer, (87) 105  
 Hydroxypropyl methylcellulose, (81) 243  
 Hydroxypropylmethylcellulose, (85) 57  
 Hygroscopicity, (85) 29  
 Hypoglycemia, (84) 129
- Ibuprofen, (84) 167; (87) 95  
 Ibuprofen matrix, (83) 95  
 Ibuprofen microsphere, (89) 9  
 Ibuprofen, (90) 35  
 Idarubicin, (89) R9  
 Image analysis, (88) 303  
 Imidazole derivative, (90) 247  
 Immune response, (85) R5; (88) 335  
 Immunological response, (88) 251  
 Implant, (81) 31  
 Improved delivery, (89) 251  
 Inclusion complex, (82) 29  
 Inclusion complexation, (85) 175  
 Indentation hardness, (81) 243  
 Indomethacin, (85) 103; (85) 113; (88) 39  
 Indragit RS100, (85) R1  
 Inflammation, (88) 251  
 Infrared spectroscopy, (81) R11; (84) 197; (86) 221  
 Inhalation flow, (81) 199  
 Inhibition, (81) 267; (85) 181  
 [<sup>111</sup>In]Indium, (87) 215  
 Injection, (83) 241  
 Injection volume, (81) 193  
 In-line drug delivery, (88) 369  
 In situ absorption, (84) 223  
 Instillation, (87) 183  
 Insulin, (83) 1; (84) 129; (86) 1; (87) 125; (88) 63; (88) 319; (89) 147  
 Insulin delivery system, (86) 1  
 Insulin-like growth factor, (85) 51  
 Interaction, (86) 59; (88) 31; (90) 181  
 Interfacial micelle formation, (89) 33  
 Interfacial polycondensation, (81) 111  
 Interfacial tension, (85) 19  
 Internal porosity, (89) 9  
 Interpolymer complex, (89) 177  
 Intersubject variation, (82) 233; (89) 9  
 Intestinal microorganism, (87) 59  
 Intra-gastric buoyancy, (86) 79  
 Intra-gastric degradation, (82) 79  
 Intramolecular aminolysis, (82) 85; (84) 175  
 Intramuscular injection, (81) 193  
 Intrasubject variation, (82) 233  
 Intratracheal administration, (88) 63  
 Intravaginal absorption, (88) 319  
 Intravenous administration, (83) 257  
 Intravenous infusion, (89) 125  
 Intrinsic dissolution rate, (82) 195; (88) 151  
 Inulin, (87) 255  
 Inverse GC, (81) 21  
 In vitro dissolution, (86) 9  
 In vitro evaluation, (82) 47  
 In vitro-in vivo correlation, (85) 113; (90) 51  
 In vitro penetration, (90) R5  
 In vitro release, (85) 103; (85) 113; (86) 159; (90) 43  
 In vivo study, (86) 259  
 Ion exchange, (85) 45; (87) 31  
 Ionic permeant, (90) 171  
 Ionic strength, (90) 151  
 Ionic strength effect, (83) 65  
 Ionization, (90) 129  
 Ionization constant, (83) 267  
 Ionized form, (89) 191  
 Ion-pair, (88) 379  
 Iontophoresis, (81) 119  
 Isobutylcyanoacrylate nanoparticles, (84) 283  
 Isocyclosporin A, (82) 79; (82) 85  
 Isomerization, (82) 79  
*cis-trans* Isomerization, (81) 179

- Isopilocarpine, (88) 397  
 Isopropyl myristate, (85) 7
- Josamycin, (88) 151
- Kaopectate, (89) 75  
 Keratin, (87) 265  
 Ketanserin tartrate, (87) 161  
 Ketobemidone, (84) 253; (88) 221; (88) 229; (88) 237; (88) 243  
 Ketoprofen, (86) 113; (88) 433  
 Killing time, (82) 107  
 Kinetics, (87) 31; (89) 51; (89) 235; (90) 239  
 Kneaded mixture, (85) 1  
 Kupffer cell, (82) 99
- $\beta$ -Lactam antibiotic, (83) 123  
 $\beta$ -Lactamase inactivation, (82) 53  
 $\beta$ -Lactamase induction, (82) 53  
 Lactonization kinetics, (88) 397  
 Lactose, (81) 199; (81) 225; (85) 121; (88) 141; (88) 159; (90) R1  
 Lactose granulation, (84) 191  
 Lactose particle size effect, (81) 205  
 Lactulose, (87) 215  
 Lag time method, (90) 161  
 Lamellar phase, (86) 137  
 Lamellar structure, (84) 205  
 Laplace transformation, (89) 199  
 Large microspheres, (89) 91  
 Laser diffraction, (88) 141  
 Latex, (87) 239; (87) 247; (90) R9  
 Lecithin, (84) 107; (84) R5; (88) 53; (90) 255  
*Leishmania donovani*, (83) 251  
 Leuprolide ion pair, (80) 141  
 Levobunolol, (82) 39  
 L929 fibroblast, (84) 13  
 Light protection, (87) 133  
 Light scattering, (88) 417  
 Linear variable displacement transformer, (84) 69  
 Lipid complex, (89) 157  
 Lipidic acid, (87) 141  
 Lipidic amino acid, (83) 123; (83) 131; (87) 141  
 Lipidic drug conjugate, (83) 131  
 Lipidic peptide, (83) 131; (87) 141  
 Lipid methylation, (81) 267  
 Lipid structure, (87) 265  
 Lipid transition, (85) 129  
 Lipofundin S, (83) 227  
 Lipophilic counterion, (90) 141  
 Lipophilic ion pair, (90) 141  
 Lipophilicity, (88) 237; (88) 243  
 Liposomal entrapment, (88) 201  
 Liposomal lipid peroxidation, (90) 221  
 Liposome, (81) 235; (84) 93; (85) 97; (87) 183; (88) 201; (88) 313; (88) 327; (88) 335; (88) 409; (89) 183; (90) 73  
 Liposome aerosol, (87) 183  
 Liposome membrane integrity, (82) 53
- Liposomes, (90) 59  
 Liposphere, (89) R9  
 Liquid-liquid distribution measurement, (89) 103  
 Liquid penetration, (82) 145; (90) 203  
 Liver, (85) 75  
 Liver targeting, (89) 91  
 Local anesthetic, (84) 33  
 Local concentration, (89) 199  
 L44O (2-(*t*-butyl)-4-cyclohexylphenyl)nicotinate *N*-oxide), (84) 93  
 Low dose drug distribution, (88) 159  
 Lubricant, (86) 131  
 Lung, (88) 63  
 Lung function, (81) 199  
 Lung targeting, (89) 91  
 Lymphatic absorption, (88) 423  
 L-Lysine, (88) 111  
 Lysine HCl, (89) 111  
 Lysophosphatidylcholine, (88) 319
- Macrolide, (88) 151  
 Macromolecule, (82) 171; (90) 95  
 Magnesium stearate, (86) 131  
 Magnetic remote control, (87) 89  
 Maltodextrin, (86) 131  
 Mannitol, (88) 141  
 Mass law, (87) 31  
 Mathematical fit, (90) 151  
 Matrix, (88) 99  
 Matrix integrity, (90) 151  
 Matrix tablet, (85) 65  
 M-cell, (84) 245  
 Mean residence time, (86) 123  
 Mean yield pressure, (81) 187; (82) 71  
 Mechanism, (90) 239  
 Mechanistic analysis, (86) 167  
 Melting behavior, (85) 103  
 Melting temperature, (83) 211  
 Membrane, (88) 1; (90) 161  
 Mercury intrusion, (84) 191  
 Mercury penetration, (84) 191  
 Mercury porosimetry, (84) 191  
 Mesalazine, (88) 177  
 Mesopore area distribution, (90) R1  
 Metabolism, (84) 59  
 Metal-ion complexation, (87) 203  
 Metered dose inhaler, (83) 163  
 Methacrylic acid copolymer, (87) 247  
 Methotrexate, (85) 189; (89) 91  
 Methotrexate-human serum albumin conjugate, (89) 91  
 4'-*O*-(4-Methoxyphenyl)acetyltylosin, (85) 87  
 Methylcellulose, (81) 75  
 Methylene group contribution, (83) 25  
 Methyl nicotinate, (87) 261; (90) 43  
 Metoclopramide, (88) 433  
 Metoprolol, (88) 391  
 Metoprolol release, (87) 89

- Mexiletine, (81) 127  
 Micelle, (83) 115; (86) 43  
 Miconazole, (90) 247  
 Microbiological assay, (82) 157  
 Microcalorimetry, (81) 153; (83) 11; (85) 199; (89) 33; (90) 19  
 Microcapsule, (81) 111; (82) 129  
 Microcrystalline cellulose, (81) 205; (81) 225; (82) 71; (83) 11; (83) 65  
 Microemulsion, (84) R5; (88) 417; (89) R9  
 Microencapsulation, (88) 39; (89) 229  
 Microparticles, (87) 215  
 Microsphere, (83) 1; (83) 273; (84) 151; (84) 245; (86) 147; (87) 21; (89) 229; (89) 235  
 Minicolumn centrifugation, (89) 157  
 Minolta® Chroma Meter, (83) 73  
 Minor component detection, (86) 211; (86) 221  
 Miotic activity, (86) 159; (88) 409  
 Mixing, (88) 159  
 Mixing kinetics, (83) 147  
 Mixing time, (83) 147  
 Mixture, (82) 135  
 Mobile order, (87) 47  
 Modeling, (86) 113  
 Modeling drug release, (83) 95  
 Modified cyclodextrins, (88) 189  
 Modified release, (84) 59  
 Modified release granule, (85) 141  
 Modified solubility parameter, (87) 47  
 Moisture, (90) R1  
 Moisture content, (81) 187  
 Moisture distribution, (84) 261  
 Moisture permeation, (84) 261  
 Moisture sorption isotherm, (84) 49  
 Moisture transfer, (84) 261  
 Molecular extinction coefficient, (82) 223  
 Molecular modeling, (88) 397; (90) 35  
 Molecular weight, (86) 107  
 Molecular weight dependence, (88) 125; (88) 405  
 Moment analysis, (89) 9  
 Monoisopropyl PVM-MA, (84) 217  
 Monolayer, (90) 59  
 Monomer carrier, (81) 103  
 Monoprotic acid, (87) 11  
 Mucoadhesion, (81) 59; (83) 221  
 Mucosal adhesion, (83) 221  
 Mucosal delivery, (88) 335  
 Mucosal permeability, (89) 41  
 Multicomponent analysis, (85) 163  
 Multilamellar liposome, (81) 235  
 Multilamellar vesicle, (89) 157  
 Multilayer coated granule, (81) 75  
 Multiple peaks, (82) 233  
 Multiple plasma peak, (83) 257  
 Muramyltripeptide-cholesterol, (89) 139  
 Myricetin, (86) 17  
 N-0923, (87) 67; (88) 165  
 Na<sup>+</sup> dependence, (88) 111  
 Naftidrofuryl, (87) 223; (87) 229  
 Nanodispersion, (87) 239  
 Nanoparticle, (87) 239; (87) 247; (89) 33  
 Nanoparticle coating, (84) 1  
 Nanoparticles, (84) 23; (85) 7; (90) R9  
 Naproxen, (82) 129; (86) 131  
 Narcotic analgesic, (84) 253  
 Nasal, (87) 125  
 Nasal absorption, (84) 129  
 Nasal administration, (83) 1; (88) 335; (89) 147  
 Nasal membrane permeability, (84) 129  
 Nebuliser, (85) 203  
 Nebulizer, (86) 1  
 Nedocromil, salt, (82) 117  
 Nerve growth factor, (87) 21  
 Neutral permeant, (90) 171  
 Nicotinate-induced erythema, (83) 73  
 Nifedipine, (84) 59; (84) 161; (85) 1; (87) 133  
 Nitrofurazone, (82) 215; (82) 223; (82) 229  
 Nitroglycerin, (82) R1  
 NMR, (81) 179; (87) 1; (88) 177; (90) 35  
 Non-aqueous non-polar suspension, (83) 163  
 Non-Fickian release, (82) 61  
 Nonionic surfactant, (88) 211  
 Nonionized form, (89) 191  
 Nonlinear regression, (84) 233  
 Non-steroidal anti-inflammatory agent, (89) 51  
 Nonsteroidal anti-inflammatory drug, (83) 73  
 Norfloxacin, (87) 73  
 Norfloxacin-metal ion interaction, (87) 73  
 Normalized solid fraction, (89) R17  
 Novel compound, (83) 39  
 Nuclear Overhauser effect, (90) 35  
 Numerical deconvolution, (85) 65; (87) 229  
 Nystatin tablet, (88) 9  
 Octakis(2,6-di-*O*-methyl)- $\gamma$ -cyclodextrin, (82) 29  
 Octan-1-ol, (83) 25  
 Octanol/water partition coefficient, (83) 123  
 Ocular bioavailability, (81) 59; (88) 409  
 Ocular insert, (86) 159  
 Oily carrier, (86) 25  
 Ointment, (82) 39  
<sup>18</sup>O labeling, (90) 239  
 Oleic acid, (85) 7; (87) 175; (88) 423  
 Ophthalmic drug delivery, (83) 177  
 Optical rotation, (82) 151  
 Optimization, (86) 107; (88) 75  
 Oral absorption, (84) 245; (86) 239  
 Oral administration, (81) 49; (83) 155; (83) 257; (88) 335  
 Oral availability, (81) 133  
 Oral drug delivery, (87) 105  
 Oral mucosa, (82) 165

- Ordered mixture, (81) 199; (90) 1  
 Organic acid, (81) 133  
 Osmolarity, (85) 19  
 Osteosarcoma, (89) 229  
 Overlapping equilibria, (88) 15  
 Oxazepam, (90) 1  
 Oxidation, (90) 19  
 Oxidative polymerization, (88) 177  
 Oxodipin/PEG 6000/Tween 20, (89) 119  
 Oxprenolol, (84) 175  
 Oxprenolol ester, (84) 175  
 Oxygen radical, (87) 79
- Packaging, (83) 59  
 Paper chromatography, (82) 215  
 Paracetamol, (81) 187  
 Parenteral nutrition, (81) 1; (87) 167  
 Partial least-squares, (85) 163  
 Particle rearrangement, (89) R17  
 Particle size, (81) 243; (83) 227; (89) 9  
 Particle size distribution, (90) 105  
 Particle size effect, (81) 225  
 Particle size measurement, (88) 303  
 Partition, (90) 129  
 Partition coefficient, (82) 223; (83) 25; (83) 39; (84) 175; (88) 379; (90) 141  
 Partitioning, (83) 25; (84) 117  
 Peak asymmetry, (86) 221  
 Pectin, (89) 177  
 PEG coprecipitate, (84) 223  
 PEG-lipid, (88) 327  
 Pellet, (86) 113  
 Pellet quality, (86) 187  
 Pellets, (84) 59  
 Penetration enhancement, (82) R1; (84) 117; (87) 67  
 Penetration enhancer, (82) 171; (85) 7; (85) 129; (87) 261; (87) 265; (88) 125; (89) 81  
 Penetration, in vitro, (87) 67  
 Penetration mechanism, (87) 175  
 Pentamidine isethionate, (85) 203  
 Peptidase inhibitor, (89) 169  
 Peptide delivery, (90) 255  
 Peptide partitioning, (90) 141  
 Percolation theory, (90) 213  
 Percutaneous absorption, (82) 171; (87) 261; (88) 89; (89) 81; (89) 199; (90) 43; (90) 129  
 Percutaneous absorption enhancer, (81) 39  
 Percutaneous penetration, (84) 93; (87) 175; (90) R5  
 Perfluorocarbon emulsion, (88) 171  
 Permeability, (84) 117; (85) 7; (85) 181; (87) 37; (88) 125; (88) 237; (90) 95  
 Permeable support, (83) 197  
 Permeation, (84) 223; (90) 161  
 Permsselectivity, (88) 111  
 Peyer's patches, (84) 245; (86) 239  
 Pharmaceutical powder, (90) 203
- Pharmacokinetics, (81) 143; (82) 67; (82) 157; (85) 75; (86) 1; (87) 183; (87) 229; (88) 433; (89) 245  
 Pharmacoscintigraphy, (83) 155  
 Phase diagram, (83) 211; (87) 95  
 Phase separation, (82) 129; (87) 239  
 Phase study, (84) R5  
 Phase transformation, (85) 149  
 Phase transition, (84) 205; (89) 183  
 pH, (88) 151  
 pH adjustment, (84) 33  
 pH change release test, (85) 141  
 pH-changing medium, (85) 57  
 pH-dependent solubility, (85) 141  
 pH effect, (83) 65  
 pH effects, (86) 167  
 pH-independent sustained-release granule, (81) 49  
 pH-rate profile, (90) 239  
 Phenol, (81) 253  
 Phenylbutazone, (89) 183  
 Phenylpropanolamine, (85) 65; (89) 223  
 Phenytoin, (81) 263; (86) 175  
 Phosphatidylcholine, (84) 161; (88) 1  
 Phospholipid, (85) 189; (88) 171  
 Phospholipid bilayer, (89) 183  
 Photodiode array detection, (84) 279  
 Photolysis, (88) 275  
 Photon correlation spectroscopy, (83) 139; (88) 327  
 Photosensitizer, (90) 221  
 Photostability, (83) 263; (86) 25  
 Physical mixture, (89) 177  
 Physical model, (81) 89  
 Physicochemical characterization, (88) 261  
 Physicochemical property, (87) 59  
 Physiological model, (85) 75  
 Pigment, (86) 49  
 Pilocarpine, (86) 159; (88) 397; (88) 409  
 Placental perfusion, (88) 313  
 Placental transfer, (88) 313  
 Plasma, (87) 255  
 Plasma concentration dependence, (81) 127  
 Plasma pharmacokinetics, (88) 327  
 Plastic deformation, (81) 243  
 Plastic infusion tubing, (88) 351  
*Pneumocystis carinii* pneumonia, (85) 203  
 Polarity, (83) 163  
 Polar lipid, (86) 137  
 Polarography, (90) 181  
 Poloxamer 407, (83) 273; (88) 327; (89) 25; (89) 33  
 Poloxamine 908, (89) 25; (89) 33  
 Polyacrylic acid, (81) 59  
 Poly(acrylic acid), (82) 61  
 Polyacrylic acid, (83) 221  
 Poly( $\epsilon$ -caprolactone), (84) 85  
 Polycyclic aromatic hydrocarbon, (87) 47  
 Polydispersed system, (86) 113  
 Poly(dl-lactic acid), (86) 107; (87) 247  
 Polyester nanoparticles, (89) 25

- Polyethylene glycol, (88) 125  
 Polyethylene, (82) 71  
 Polyethylene glycol, (81) 263; (83) 47; (83) 211; (84) 161; (89) 199; (90) 105  
 Polyethylene glycol base, (89) 111  
 Polyisobutylene, (82) 129  
 Polylactic acid copolymer, (89) 251  
 Poly(lactic-co-glycolic)acid, (89) 235  
 Polylactide, (84) 151  
 Poly(L-proline)II, (83) 139  
 Polymer, (83) 1; (86) 159; (89) 177  
 Polymer carrier, (81) 103  
 Polymer concentration, (89) 235  
 Polymer degradation, (84) 1  
 Polymer erosion, (85) R5  
 Polymeric aqueous dispersion, (87) 247  
 Polymeric Prodrug, (82) 205  
 Polymethyl methacrylate, (89) 229  
 Polymixin, (90) 59  
 Polymorph, (81) 169; (88) 275  
 Polymorphism, (85) 163; (87) 1; (88) 261  
 Polyoxyethyleneglycol surfactants, (81) R5  
 Polypeptide antibiotic, (89) 261  
 Polysorbate 80, (82) 67  
 Poly(styrene), (90) R9  
 Polystyrene latex, (86) 239  
 Polystyrene latex absorption, (84) 245  
 Polystyrene particle, (89) 33  
 Polyvinyl alcohol, (81) 59; (83) 177  
 Polyvinylchloride, (88) 351  
 Pore size distribution, (84) 191  
 Porosity, (81) 243  
 Potentiometry, (90) 181  
 Powdered form, (86) 25  
 Powder mixture, (85) 121  
 Powell's algorithm, (88) 369  
 Precipitation, (84) 107; (88) 53  
 Precorneal residence, (83) 177  
 Prednisolone, (89) 81  
 Pretreatment, (88) 89  
 Processing, (83) 187  
 Prodrug, (81) 253; (82) 85; (82) 91; (84) 253; (86) 175; (87) 59; (88) 221; (88) 229; (88) 237; (88) 243; (89) 65  
 Profile fitting, (81) 169  
 Progestational steroid, (89) 41  
 Progesterone, (89) 81  
 Prolyl endopeptidase, (82) 91  
 Promoting effect, (89) 169  
 Propranolol, (81) 193; (81) 235; (82) 61; (84) 117; (88) 423; (90) R5  
 Propylene glycol, (85) 7  
 Prostaglandin, (83) 171  
 Protein adsorption, (86) 89  
 Protein transition, (85) 129  
 Proteolytic degradation, (84) 129  
 Proteolytic enzyme inhibitor, (81) 119  
 Protonation macroconstant, (89) 261  
 Pullulan, (89) 207  
 Pulmonary absorption, (87) 183  
 Pulmonary delivery, (87) 183  
 Pulmonary route, (86) 1  
 Pulmonary toxicity, (87) 183  
 Pulsed release, (87) 89  
 PVC bag, (89) 125  
 PVP, (82) 145  
 Pyrazole formation, (82) 151  
 QSAR, (83) 123  
 Quantitative analysis, (85) 163  
 Quantitative assessment, (83) 73  
 Quercetin, (86) 17  
 Quinoline Yellow (E 104), (83) 263  
 Rabbit, (82) 67; (83) 273; (86) 159; (87) 59; (87) 125; (88) 409; (89) 147  
 Racemic compound, (87) 95  
 Radical scavenger, (90) 221  
 Raman spectroscopy, (81) R11  
 Ram extruder, (81) 225; (86) 187  
 Ram extruder (including die diameter), (81) 205  
 Ranitidine, (82) 233  
 Rat, (81) 127; (81) 133; (83) 1; (83) 273; (84) 223; (88) 63; (88) 165  
 Rate control, (82) R1  
 Rat prostate, (81) 31  
 Rat skin, (87) 67  
 Reactive medium, (84) 167  
 Receptor-mediated endocytosis, (85) 75  
 Recombinant human granulocyte colony-stimulating factor (rhG-CSF), (81) 133  
 Recrystallization temperature, (85) 87  
 Redispersibility, (86) 25  
 Reduced adherence, (84) 77; (86) 193  
 Relative bioavailability, (86) 147  
 Relative density, (81) 187  
 Relative humidity, (83) 59  
 Release-diffusion, (81) 67  
 Release, in vivo, (85) 65  
 Release mechanism, (81) 75; (88) 99; (89) 19  
 Releasing area, (88) 99  
 Residence-time distribution, (88) 369  
 Response surface, (86) 107  
 Reticuloendothelial system, (82) 99  
 Reticuloendothelial system, (90) 73  
 Reversed-phase HPLC, (84) R1  
 Reversed-phase ion-pair HPLC, (82) 179  
 Reverse-phase evaporation liposome, (89) 133  
 Rose bengal partitioning, (84) 23  
 Rotary fluidized-bed, (88) 75  
 Rotary tablet machine, (88) 285  
 Ruggedness testing, (88) 23  
 Salbutamol, (81) 199  
 Salbutamol sulfate, (86) 153

- Salicylic acid, (85) 129; (88) 23  
 Salicylic acid-methionine conjugate, (87) 59  
 Salicylic acid-tyrosine conjugate, (87) 59  
 Saliva, (81) 127  
 Saliva concentration, (82) 233  
 Saliva enzyme-catalyzed hydrolysis, (88) 229  
 Saliva esterase, (88) 221  
 Saliva/plasma concentration ratio, (81) 127  
 Salivary clearance, (81) 127  
 Salt effect, (85) 57  
 Salting-out, (87) 239; (87) 247  
 Scaling concepts, (90) 203  
 Scanning electron microscopy, (82) 195; (86) 247; (87) 1  
 Schiff base, (85) 199  
 Secondary structure, (85) 39  
 Selective drug delivery, (87) 37  
 Self-aminolysis, (88) 189  
 Semisolid topical dosage form, (86) 9  
 Separation, (81) 199  
 Shape, (83) 187  
 Shear modulus, (81) 243  
 Sheep, (88) 319  
 Shelf-life, (84) 279  
 Sialic acid, (90) 73  
 Sideway filling, (88) 285  
 Sieve analysis, (88) 141  
 Silicone elastomer latex, (87) 117  
 Simulation, (86) 49; (88) 351; (90) 161  
 Simvastatin, (89) 133  
 Single-shot immunization, (90) 255  
 Singular points, (87) 11  
 Size, (83) 187  
 Skin absorption, (82) R1  
 Skin penetration, (84) 253  
 Skin permeation, (86) 167; (89) 191  
 Skin solubility, (83) 171  
 Slow release, (84) 33  
 Slow release formulation, (86) 123  
 Slow release mechanism, (85) 51  
 Small microspheres, (89) 91  
 Small unilamellar vesicle, (89) 157  
 Sodium acetate, (84) 217  
 Sodium carboxymethylcellulose, (89) 223  
 Sodium chloride, (88) 39  
 Sodium deoxycholate, (85) 129; (89) 169  
 Sodium dodecyl sulfate, (83) 47; (83) 53; (90) 105  
 Sodium lauryl sulfate, (81) R1; (85) 129  
 Sodium metabisulfite, (90) 19  
 Sodium salicylate, (83) 53  
 Sodium starch glycolate, (83) 65  
 Sodium stibogluconate, (83) 251  
 Sodium valproate, (81) 67  
 Soft drug, (89) 51; (89) 65  
 Solid dispersion, (83) 211; (84) 161; (88) 31; (90) 105  
 Solid dosage form, (81) 103  
 Solid dosage form excipient, (83) 65  
 Solid-liquid phase diagram, (86) 211; (86) 221  
 Solid-phase extraction, (87) 223  
 Solid solution, (83) 47  
 Solid-state, (88) 275  
 Solid state decomposition, (83) 87  
 Solid-state NMR, (83) 47  
 Solubility, (81) R1; (82) 229; (83) 211; (85) 203; (87) 47; (87) 95; (87) 203; (88) 151; (90) 1; (90) 129  
 Solubility diagram, (90) 247  
 Solubility prediction, (84) 167; (88) 437  
 Solubility-temperature dependence, (84) 233  
 Solubilization, (81) R1; (82) 223; (85) R1  
 Solute-solvent interaction, (83) 25  
 Solution conformation, (83) 25  
 Solution thermodynamics, (84) 233; (87) 47  
 Solvatochromic polarity parameter, (88) 437  
 Solvent evaporation, (89) 25  
 Sorption, (85) 29; (90) R1  
 Sorption-desorption moisture transfer model, (84) 261  
 Specialized transport system, (82) 165  
 Specific tablet surface area, (85) 121  
 Spectrometry, (90) 181  
 Spectrophotometry, (86) 17; (87) 73; (88) 15  
 Spherical granule, (81) 205; (81) 225  
 Spheroid, (83) 187  
 Spheroidal granule, (85) 209  
 Spheronisation, (83) 187  
 Spheronization, (86) 187  
 Spin-lattice relaxation time, (87) 1  
 Spin-spin relaxation time, (87) 1  
 Spray drying, (85) 87  
 Spreading coefficient, (83) 163  
 Stability, (81) 1; (81) 153; (81) 179; (82) 79; (83) 11; (83) 87; (83) 227; (84) 175; (85) 87; (86) 231; (87) 133; (87) 167; (89) 125; (89) 213; (90) 19  
 Stability constant, (90) 247  
 Stability-indicating assay, (82) 215  
 Stability study, (84) 279  
 Stabilization, (82) 29; (88) 189; (90) 187  
 Statistical analysis, (88) 23  
 Statistical comparison, (82) 157  
 Statistical model, (83) 59  
 Statistical moments analysis, (90) 51  
 Steady state, (90) 161  
 Steer, (89) 251  
 STELLA® simulation, (84) 217  
 Steric effect, (83) 39  
 Steric stabilization, (89) 25  
 Storage, (90) 105  
 Storage effect, (89) 1  
 Stratum corneum, (81) 39; (81) R11; (83) 171; (84) 205; (87) 175; (87) 265  
 Structural effect, (83) 267; (88) 379  
 Structural effects, (87) 203  
 Structure, (83) 47  
 Structure-activity relationship, (85) 199  
 Structure determination, (88) 177  
 Subcutaneous route, (86) 1

- Subinhibitory concentration, (87) 195  
 Submicronic emulsion, (89) 139  
 Submicron particle, (84) 107  
 Submicron particles, (88) 53  
 Substituent constant, (83) 25  
*p*-Substituent effect, (90) 239  
 Substrate protection, (82) 53  
 Sulfamethoxazole, (85) 163  
 Sulfamethoxazole-trimethoprim, (85) 209  
 Sulfamethoxazole-trimethoprim formulation, (90) 51  
 Sulfonamide, (88) 437  
 Suppository, (81) 67; (82) 67; (85) 103; (85) 113; (86) 231  
 Surface area coverage, (90) 1  
 Surface binding, (86) 89  
 Surface charge, (84) 1  
 Surface energy, (83) 163  
 Surface hydrophobicity, (84) 1; (84) 23; (89) 25  
 Surface modification, (89) 25; (90) 73  
 Surface tension viscous flow model, (90) 203  
 Surfactant, (81) 67; (81) 111; (83) 115; (85) 19; (85) R1; (87) 261  
 Suspension, (84) 107; (88) 53  
 Sustained release, (83) 155; (85) 45; (89) 229; (90) 151; (90) 255  
 Sustained-release kinetics, (87) 31  
 Sustained-release pellet, (83) 95  
 Sustained-release tablets, (86) 79  
 Swelling, (88) 99  
 Swelling control, (89) 19  
 Swelling interface number, (88) 99  
 Synperonic T304, (81) R1  
 Synthesis, (83) 233  
 Synthetic membrane, (90) 43  
 Systemic absorption, (84) 217
- Tablet, (84) 191; (89) 223  
 Tablet coating, (87) 133  
 Tablet disintegration, (86) 259  
 Tablet formation, (90) 213  
 Tableting, (88) 261  
 Tablet properties, (88) 9; (89) 1  
 Tablets, (87) 215; (89) 19  
 Tablet strength, (85) 121; (88) 261  
 Tablet surface area, (90) R1  
 Tangential spray, (86) 247  
 Tap density, (89) R17  
 Taurocholic acid transport, (83) 197  
<sup>99m</sup>Tc]Technetium, (87) 215  
 Temperature effect, Nucleophile effect, (90) 239  
 Tenormin<sup>®</sup>, (89) 245  
 Tensile strength, (90) 213  
 Tensile test, (82) 61  
 Tensiometry, (86) 175  
 Ternary system, (89) 119  
 Tetracycline, (89) 75  
 Tetraphenyl tin, (86) 107  
 Theophylline, (82) 117; (83) 59; (86) 231  
 Theophylline monohydrate, (85) 149  
 Theophylline tablet, (87) 117  
 Thermal analysis, (89) 119  
 Thermodynamic parameters, (82) 223; (82) 229  
 Thermodynamics, (83) 115  
 Thermogravimetric analysis, (82) 185  
 Thermomicroscopy, (82) 185  
 Thermoreversible drug delivery system, (86) 137  
 Thimerosal, (89) 213  
 Thiol reduction, (89) 51  
 Thiosalicylic acid, (89) 213  
 Tiaprofenic acid, (83) 155  
 Tight junctions, (90) 229  
 Timolol, (81) 59; (84) 217  
 Timolol maleate, (89) 235  
 Tissue distribution, (84) 273; (90) 81  
 Tissue regeneration, (85) 51  
 Titanium dioxide, (87) 133  
 Titration curve, (87) 11  
 dl- $\alpha$ -Tocopherol nicotinate, (84) 93  
 Tolmetin sodium, (86) 131  
 Topical corticosteroid, (86) 201  
 Topical formulation, (86) 147; (90) 43  
 Top spray, (86) 247  
 Toxicity, (88) 243  
 TPN, (83) 227; (87) 167  
 Trace element, (81) 1  
 Transdermal absorption, (81) 119  
 Transdermal delivery, (83) 171; (84) 253; (88) 391  
 Transdermal drug delivery, (82) 39; (82) R1  
 Transdermal penetration, (88) 165  
 Transmembrane delivery, (87) 141  
 Transmission electron microscopy, (86) 175  
 Transport mechanism, (90) 171  
 Triple helix, (83) 139  
 Tris, (82) 135  
 Tromethamine, (89) 213  
 Trypsin inhibitor, (81) 133  
 Turbidimetry, (90) R9
- Ubidecarenone, (86) 25  
 Ultraviolet light absorber, (82) 223  
 Unilamellar liposome, (81) 235  
 Unilamellar liposome encapsulation, (82) 53  
 Uptake, (88) 351  
 Urea, (82) 229; (89) 111  
 Urea impregnation, (82) 215  
 Ussing chamber, (87) 125; (89) 147
- Vaccine delivery, (85) R5  
 Vaginal absorption, (89) 169  
 Validation, (88) 303  
 Valine, (85) 7  
 Vancomycin, (89) 261  
 Van't Hoff plot, (84) 233  
 Variability, (86) 69  
 Variable drug release, (87) 89



- Vasoconstriction, (86) 201  
Vasodilator, (87) 223; (87) 229  
Vasopressin, (81) 119  
Verapamil, (86) 167  
Verapamil HCl, (89) 111  
Vesicular delivery, (83) 251  
Viability, (87) 125  
Vinylbenzaldehyde, (81) 103  
Viscosity, (85) 19  
Vitamin, (81) 1  
Vitamin A, (86) 147  
Vitamin D<sub>3</sub>, (84) 151  
Vitamin E, (88) 211
- Water, (81) 21; (81) 153; (83) 11  
Water content determination, (82) 117  
Water, [<sup>3</sup>H]-, (81) 143  
Water-soluble carrier, (89) 207  
Water-soluble prodrug, (81) 263  
Water, stoichiometry, (82) 117  
Weak base, (87) 161  
Weibull distribution, (88) 369  
Weibull transformation, (88) 23
- Weight variation, (88) 285  
Wet granulation, (87) 117; (88) 261  
Wet granulation: Torque rheometry, (83) 147  
Wettability, (82) 145; (90) 203  
Wetting, (82) 145  
Within-individual variability, (86) 123  
Work of adhesion, (83) 163  
Work of cohesion, (83) 163  
Wound healing, (85) 51
- Xanthine oxidase, (86) 17  
X-ray diffraction, (84) 197; (87) 1  
X-ray powder diffraction, (81) 169; (83) 47; (90) 105  
X-ray powder diffractometry, (82) 195  
Xylitol, (90) 105  
Xylometazoline, (86) 59
- Young's modulus of elasticity, (90) 213
- Zero-order release, (84) 85  
Zero surface coverage, (81) 21  
Zeta potential, (84) 1; (87) 167